<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antidepressants for people with epilepsy and depression - Maguire, MJ - 2021 | Cochrane Library</title> <meta content="Antidepressants for people with epilepsy and depression - Maguire, MJ - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010682.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antidepressants for people with epilepsy and depression - Maguire, MJ - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010682.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010682.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antidepressants for people with epilepsy and depression" name="citation_title"/> <meta content="Melissa J Maguire" name="citation_author"/> <meta content="Leeds General Infirmary" name="citation_author_institution"/> <meta content="maguirem@doctors.org.uk" name="citation_author_email"/> <meta content="Anthony G Marson" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="Sarah J Nevitt" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD010682.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/04/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010682.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010682.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010682.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antidepressive Agents [adverse effects, *therapeutic use]; Bias; Cognitive Behavioral Therapy; Depression [*drug therapy, etiology]; Epilepsy [chemically induced, *drug therapy, psychology]; Non-Randomized Controlled Trials as Topic; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010682.pub3&amp;doi=10.1002/14651858.CD010682.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="mV7VuqgF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010682\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010682\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","pt","ko","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010682.pub3",title:"Antidepressants for people with epilepsy and depression",firstPublishedDate:"Apr 16, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010682.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010682.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010682.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010682.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010682.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010682.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010682.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010682.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010682.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010682.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7325 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010682.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-sec-0089"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-sec-0083"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/appendices#CD010682-sec-0094"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/table_n/CD010682StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/table_n/CD010682StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antidepressants for people with epilepsy and depression</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/information#CD010682-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Melissa J Maguire</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/information#CD010682-cr-0005">Anthony G Marson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010682.pub3/information#CD010682-cr-0006">Sarah J Nevitt</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/information/en#CD010682-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 April 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010682.pub3">https://doi.org/10.1002/14651858.CD010682.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010682-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010682-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010682-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010682-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010682-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010682-abs-0006">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010682-abs-0001" lang="en"> <section id="CD010682-sec-0001"> <h3 class="title" id="CD010682-sec-0001">Background</h3> <p>Depressive disorders are the most common psychiatric comorbidity in people with epilepsy, affecting around one‐third, with a significant negative impact on quality of life. There is concern that people may not be receiving appropriate treatment for their depression because of uncertainty regarding which antidepressant or class works best, and the perceived risk of exacerbating seizures. This review aimed to address these issues, and inform clinical practice and future research. </p> <p>This is an updated version of the original Cochrane Review published in Issue 12, 2014. </p> </section> <section id="CD010682-sec-0002"> <h3 class="title" id="CD010682-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of antidepressants in treating depressive symptoms and the effect on seizure recurrence, in people with epilepsy and depression. </p> </section> <section id="CD010682-sec-0003"> <h3 class="title" id="CD010682-sec-0003">Search methods</h3> <p>For this update, we searched CRS Web, MEDLINE, SCOPUS, PsycINFO, and ClinicalTrials.gov (February 2021). We searched the World Health Organization Clinical Trials Registry in October 2019, but were unable to update it because it was inaccessible. There were no language restrictions. </p> </section> <section id="CD010682-sec-0004"> <h3 class="title" id="CD010682-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and prospective non‐randomised studies of interventions (NRSIs), investigating children or adults with epilepsy, who were treated with an antidepressant and compared to placebo, comparative antidepressant, psychotherapy, or no treatment for depressive symptoms.  </p> </section> <section id="CD010682-sec-0005"> <h3 class="title" id="CD010682-sec-0005">Data collection and analysis</h3> <p>The primary outcomes were changes in depression scores (proportion with a greater than 50% improvement, mean difference, and proportion who achieved complete remission) and change in seizure frequency (mean difference, proportion with a seizure recurrence, or episode of status epilepticus). Secondary outcomes included the number of participants who withdrew from the study and reasons for withdrawal, quality of life, cognitive functioning, and adverse events. </p> <p>Two review authors independently extracted data for each included study. We then cross‐checked the data extraction. We assessed risk of bias using the Cochrane tool for RCTs, and the ROBINS‐I for NRSIs. We presented binary outcomes as risk ratios (RRs) with 95% confidence intervals (CIs) or 99% CIs for specific adverse events. We presented continuous outcomes as standardised mean differences (SMDs) with 95% CIs, and mean differences (MDs) with 95% CIs.  </p> </section> <section id="CD010682-sec-0006"> <h3 class="title" id="CD010682-sec-0006">Main results</h3> <p>We included 10 studies in the review (four RCTs and six NRSIs), with 626 participants with epilepsy and depression, examining the effects of antidepressants. One RCT was a multi‐centre study comparing an antidepressant with cognitive behavioural therapy (CBT). The other three RCTs were single‐centre studies comparing an antidepressant with an active control, placebo, or no treatment. The NRSIs reported on outcomes mainly in participants with focal epilepsy before and after treatment for depression with a selective serotonin reuptake inhibitor (SSRI); one NRSI compared SSRIs to CBT.  </p> <p>We rated one RCT at low risk of bias, three RCTs at unclear risk of bias, and all six NRSIs at serious risk of bias. We were unable to conduct any meta‐analysis of RCT data due to heterogeneity of treatment comparisons. We judged the certainty of evidence to be moderate to very low across comparisons, because single studies contributed limited outcome data, and because of risk of bias, particularly for NRSIs, which did not adjust for confounding variables. </p> <p>More than 50% improvement in depressive symptoms ranged from 43% to 82% in RCTs, and from 24% to 97% in NRSIs, depending on the antidepressant given. Venlafaxine improved depressive symptoms by more than 50% compared to no treatment (mean difference (MD) ‐7.59 (95% confidence interval (CI) ‐11.52 to ‐3.66; 1 study, 64 participants; low‐certainty evidence); the results between other comparisons were inconclusive. Two studies comparing SSRIs to CBT reported inconclusive results for the proportion of participants who achieved complete remission of depressive symptoms.  </p> <p>Seizure frequency data did not suggest an increased risk of seizures with antidepressants compared to control treatments or baseline. Two studies measured quality of life; antidepressants did not appear to improve quality of life over control. No studies reported on cognitive functioning. </p> <p>Two RCTs and one NRSI reported comparative data on adverse events; antidepressants did not appear to increase the severity or number of adverse events compared to controls. The NSRIs reported higher rates of withdrawals due to adverse events than lack of efficacy. Reported adverse events for antidepressants included nausea, dizziness, sedation, headache, gastrointestinal disturbance, insomnia, and sexual dysfunction.  </p> </section> <section id="CD010682-sec-0007"> <h3 class="title" id="CD010682-sec-0007">Authors' conclusions</h3> <p>Existing evidence on the effectiveness of antidepressants in treating depressive symptoms associated with epilepsy is still very limited. Rates of response to antidepressants were highly variable. There is low certainty evidence from one small RCT (64 participants) that venlafaxine may improve depressive symptoms more than no treatment; this evidence is limited to treatment between 8 and 16 weeks, and does not inform longer‐term effects. Moderate to low evidence suggests neither an increase nor exacerbation of seizures with SSRIs.  </p> <p>There are no available comparative data to inform the choice of antidepressant drug or classes of drug for efficacy or safety for treating people with epilepsy and depression. </p> <p>RCTs of antidepressants utilising interventions from other treatment classes besides SSRIs, in large samples of patients with epilepsy and depression, are needed to better inform treatment policy. Future studies should assess interventions across a longer treatment duration to account for delayed onset of action, sustainability of treatment responses, and to provide a better understanding of the impact on seizure control. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010682-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010682-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010682-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010682-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010682-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010682-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD010682-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010682-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010682-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010682-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010682-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010682-abs-0002" lang="en"> <h3>Antidepressants for people with epilepsy and depression</h3> <p><b>Background</b> </p> <p>Depressive disorders occur in approximately one‐third of people with epilepsy, often requiring antidepressant treatment. However, depression often goes untreated in people with epilepsy, partly due to fear that antidepressants might cause seizures. There are different classes of antidepressants, however they all aim to increase key nerve chemicals in the brain, thereby alleviating depressive symptoms. </p> <p><b>Characteristics of studies</b> </p> <p>We found ten studies that included 626 patients with epilepsy and depression treated with an antidepressant. Four were randomised controlled trials, and six were non‐randomised prospective cohort studies. The studies observed the effect of different antidepressants, mainly a class of antidepressant called a selective serotonin reuptake inhibitor (SSRI). One randomised controlled trial and one prospective study also observed the effect of cognitive behavioural therapy on depression. </p> <p><b>Results</b> </p> <p>Taking all the evidence into account, the review found that there is very limited evidence that antidepressants decrease depressive symptoms more than other treatments, placebo, or no treatment in epilepsy. There was limited information on the effect of antidepressants on seizure control, however in the studies reporting this outcome there did not appear to be any significant worsening of seizures. The evidence is current to February 2021. </p> <p><b>Quality of the studies</b> </p> <p>We assessed the studies with regard to bias and quality. Overall, the quality of the evidence was rated as moderate to low for the clinical trials and low to very low for the non‐randomised prospective cohort studies. Large, high quality trials of antidepressants are needed to examine how different classes of antidepressant compare, and what impact they are likely to have on seizure control. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010682-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010682-sec-0089"></div> <h3 class="title" id="CD010682-sec-0090">Implications for practice</h3> <section id="CD010682-sec-0090"> <p>Existing evidence on the effectiveness of antidepressants in treating depressive symptoms associated with epilepsy is still very limited. There is low to moderate certainty evidence from two RCTs that venlafaxine, sertraline, and CBT may reduce depressive symptoms. Sertraline and CBT may improve quality of life, but moderate certainty evidence did not find one superior to the other. We have no high certainty evidence to inform the choice of antidepressant drug or class of drug for treating depression in people with epilepsy. None of the treatments appeared to increase seizure activity, but there are no available comparative data on antidepressant classes and safety in relation to seizures. </p> </section> <h3 class="title" id="CD010682-sec-0091">Implications for research</h3> <section id="CD010682-sec-0091"> <p>Randomised controlled trials of antidepressants, utilising interventions from other treatment classes besides SSRIs, in large cohorts of participants with epilepsy and depression, are needed to better inform treatment policy in the future. The studies need to be of longer duration to assess efficacy of treatment responses and provide better understanding on the impact of seizure control.  </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010682-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010682-sec-0008"></div> <div class="table" id="CD010682-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Paroxetine compared to doxepin for people with epilepsy and depression</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Paroxetine compared to doxepin for people with epilepsy and depression</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with epilepsy and depression<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> paroxetine<br/><b>Comparison:</b> doxepin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>doxepin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>paroxetine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&gt; 50% reduction in depressive symptoms</b> </p> <p><i>Follow‐up: 8 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>706 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>819 per 1000</b><br/>(621 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b> <br/>(0.88 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean depression scores</b> </p> <p>(HAMD scores; lower = better)</p> <p><i>Follow‐up: 8 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HAMD depression score in the intervention groups was<br/><b>0.65 higher</b><br/>(2.15 lower to 3.45 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizure frequency</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> </p> <p><i>Follow‐up: 8 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b><br/>(1 to 242) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.15</b> <br/>(0.01 to 2.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>doxepin: 3 withdrew</p> <p>paroxetine: 0 withdrew</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p><i>Follow‐up: 8 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Reported adverse events: blurred vision, dizziness, dry mouth, sleep disorders, and urinary retention </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Reported adverse events: blurred vision, dizziness, dry mouth, and sleep disorders</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant differences between treatment groups for any reported adverse events </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b>  is the event rate in the doxepin group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HAMD:</b> Hamilton Rating Scale for Depression; <b>NA</b> : not applicable;<b> RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty.</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty,</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty.</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty.</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Certainty of the evidence downgraded for imprecision, because only one small study contributed to the outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010682-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Amitriptyline compared to nomifensine for people with epilepsy and depression</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Amitriptyline compared to nomifensine for people with epilepsy and depression</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with epilepsy and depression<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> amitriptyline<br/><b>Comparison:</b> nomifensine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>nomifensine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>amitriptyline</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&gt; 50% reduction in depressive symptoms</b> </p> <p><i>Follow‐up: 12 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>786 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>432 per 1000</b><br/>(220 to 833) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.55</b> <br/>(0.28 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean depression scores</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure frequency</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is the event rate in the nomifensine group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NA</b> : not applicable;<b> RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty.</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty,</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty.</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty.</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Certainty of the evidence downgraded twice for imprecision, because only very small study contributed limited outcome data. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010682-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Venlafaxine compared to no treatment for people with epilepsy and depression</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Venlafaxine compared to no treatment for people with epilepsy and depression</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with epilepsy and depression<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> venlafaxine<br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>venlafaxine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&gt; 50% reduction in depressive symptoms</b> </p> <p><i>Follow‐up: 8 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>406 per 1000</b><br/>(149 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.25</b> <br/>(1.19 to 8.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean depression scores</b> </p> <p>(HAMD scores; lower = better)</p> <p><i>Follow‐up: 8 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HAMD depression score in the intervention group was<br/><b>7.59 lower</b><br/>(11.52 lower to 3.66 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizure frequency</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/>(0 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognitive functioning</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b>  is the event rate in the no treatment group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HAMD:</b> Hamilton Rating Scale for Depression; <b>NA</b> : not applicable;<b> RCT</b> : randomised controlled trial;  <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty.</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty,</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty.</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty.</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Certainty of the evidence downgraded for imprecision, because only one small study contributed to the outcomes. <br/><sup>b</sup>Certainty of the evidence downgraded once due to risk of bias; unclear methodological information provided regarding randomisation and allocation concealment. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010682-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sertraline compared to cognitive behavioural therapy for people with epilepsy and depression</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Sertraline compared to cognitive behavioural therapy for people with epilepsy and depression</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with epilepsy and depression<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> sertraline<br/><b>Comparison:</b> cognitive behavioural therapy (CBT) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CBT</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>sertraline</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&gt; 50% reduction in depressive symptoms</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean depression scores</b> </p> <p>(BDI scores; lower = better)</p> <p><i>Follow‐up: 16 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BDI depression score in the intervention group was <b>0.50 lower</b> (4.47 lower to 3.47 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 8 weeks: MD ‐2.50 (95% CI ‐6.28 to 1.28; 104 participants)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure frequency</b> </p> <p><i>Follow‐up: 16 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of GTCS per month in the intervention group was <b>0 lower</b> (‐0.10 lower to 0.10 higher) </p> <p>The mean frequency of focal seizures with impaired awareness per month in the intervention group was <b>3.00 lower</b> (7.81 lower to 1.81 higher)   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 with GTCS plus 75 with focal seizures</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 8 weeks:</p> <p>GTCS per month: MD ‐0.10 (95% CI ‐0.26 to 0.06; 86 participants)</p> <p>focal seizures with impaired awareness per month: MD ‐2.60 (95% CI ‐6.52 to 1.32; 75 participants) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> </p> <p><i>Follow‐up: 16 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> <p>(113 to 434 per 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> (0.64 to 2.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBT: 6 withdrew, 6 lost to follow‐up</p> <p>sertraline: 7 withdrew, 9 lost to follow‐up</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>(QOLIE‐89 scale; lower = better)</p> <p><i>Follow‐up: 16 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean QOLIE‐89 score in the intervention group was <b>3.10 higher</b> (3.41 lower to 9.61 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>at 8 weeks: MD 6.10 (95% CI ‐0.28 to 12.48; 104 participants)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p><i>Follow‐up: 16 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adverse event profile score in the intervention group was <b>2.10 lower </b>(6.21 lower to 2.01 higher)  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>low<sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sertraline resulted in more cases of tiredness than CBT (RR 3.54, 99% CI 1.40 to 8.96; 140 participants) </p> <p>Sertraline did not result in more cases of any other adverse effects than CBT.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is the event rate in the CBT group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BDI</b> : Beck Depression Inventory; <b>CBT</b> : cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>MD</b> : mean difference; <b>NA</b> : not applicable;<b> QOLIE:</b> Quality of life in Epilepsy<b>; RCT</b> : randomised controlled trial;  <b>RR:</b> risk ratio; <b>GTCS</b>: generalised tonic‐clonic seizures </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty.</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty,</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty.</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty.</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Certainty of the evidence downgraded once due to risk of bias: participants and personnel not blinded, and lack of blinding may have influenced outcome<br/><sup>b</sup>Certainty of the evidence downgraded twice due to risk of bias and imprecision: risk of recall bias as seizure frequency data at baseline was collected retrospectively, and data not available for all participants </p> <p><sup>c</sup>Certainty of the evidence downgraded once due to imprecision: adverse event data not available for all participants who received an intervention </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010682-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Citalopram (before and after treatment) for people with epilepsy and depression</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>Citalopram (before and after treatment) for people with epilepsy and depression</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with epilepsy and depression<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> citalopram<br/><b>Control:</b> before citalopram treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Citalopram (before and after)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <b>&gt; 50% reduction in depressive symptoms</b> </p> <p><i>Follow‐up: 4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 out of 45 participants (24%) showed a 50% or more improvement in depression scores after treatment compared to baseline.<br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1 NRSI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean depression scores</b> </p> <p>(HAMD scores; lower = better)</p> <p><i>Follow‐up: 8 weeks to 4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Improved depression scores were shown after citalopram compared to before (see comment) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88<br/>(2 NRSI) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD in HAMD score was 1.17 (95% CI 0.96 to 1.38), indicating improved outcomes and a large treatment effect. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure frequency</b> </p> <p><i>Follow‐up: 8 weeks to 4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88<br/>(2 NRSI) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results were mixed between studies; due to very high heterogeneity (I² = 81%), we did not present the overall effect estimate. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> </p> <p><i>Follow‐up: 8 weeks to 4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6/45 participants (13%) withdrew from one study; 0/43 from the other study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88</p> <p>(2 NRSI)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>low<sup>a</sup><br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p><i>Follow‐up: 8 weeks to 4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22/45 participants (56%) experienced adverse events in one study; 5/43 (12%) in the other study </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88</p> <p>(2 NRSI)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>low<sup>a</sup>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific adverse events reported: nausea, sexual dysfunction, headache, dizziness, drowsiness, and fatigue </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HAMD:</b> Hamilton Rating Scale for Depression; <b>NRSI</b>: non‐randomised studies of interventions </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty.</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty,</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty.</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty.</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Certainty of the evidence downgraded twice as studies were judged to be at serious risk of bias due to lack of blinding, which may have influenced participant‐recorded outcomes, and lack of adjustment for confounding variables. <br/><sup>b</sup>Certainty of the evidence upgraded once as large effect found.<br/><sup>c</sup>Certainty of the evidence downgraded due to inconsistency: substantial statistical heterogeneity was present (I² &gt; 50%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010682-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Selective serotonin reuptake inhibitors compared to cognitive behavioural therapy for people with epilepsy and depression</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p>Selective serotonin reuptake inhibitors<b>compared to cognitive behavioural therapy for people with epilepsy and depression</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with epilepsy and depression<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> selective serotonin reuptake inhibitors (SSRIs; sertraline or citalopram)<br/><b>Comparison:</b> cognitive behavioural therapy (CBT) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CBT</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SSRIs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&gt; 50% reduction in depressive symptoms</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean depression scores</b> </p> <p>(BDI scores; lower = better)</p> <p><i>Follow‐up: 12 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BDI depression score in</p> <p>the intervention group was <b>4.90 lower </b>(14.90 lower to 4.80 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15<br/>(1 NRSI) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝ </p> <p>very low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>at 6 weeks: MD ‐2.60 (95% CI ‐11.58 to 6.38; 15 participants)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure frequency</b> </p> <p><i>Follow‐up: 12 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of seizures per month in the intervention group was <b>1.60 lower</b> (5.63 lower to 2.43 higher)  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (1 NRSI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> </p> <p><i>Follow‐up: 12 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> <p>(14 to 1000 per 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.44</b>  </p> <p>(0.05 to 3.85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (1 NRSI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>a</sup><sup>,b</sup>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBT: 2 lost to follow‐up</p> <p>SSRI: 1 lost to follow‐up in the</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life ‐ QOLIE‐31 scale</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean QOLIE‐31 score in the intervention group was <b>0.50 lower </b>(19.67 lower to 18.67 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (1 NRSI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>1,2</sup>  </p> <p><b>very</b>  <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects ‐ adverse event profile</b> </p> <p><i>Follow‐up: 16 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is the event rate in the CBT group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BDI</b> : Beck Depression Inventory; <b>CBT</b> : cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>MD</b> : mean difference; <b>NA</b> : not applicable;<b> QOLIE:</b> Quality of life in Epilepsy<b>; RCT</b> : randomised controlled trial;  <b>RR:</b> risk ratio; <b>SSRI</b>: selective serotonin reuptake inhibitors </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty.</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty,</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty.</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty.</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Certainty of the evidence downgraded twice as the study was judged to be at serious risk of bias with regards to lack of blinding which may have influenced participant recorded outcomes and lack of adjustment for confounding variables.  </p> <p>2. Certainty of the evidence downgraded once due to imprecision: very small study of 15 participants, confidence intervals around effect estimates wide </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010682-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010682-sec-0009"></div> <p>This is an updated version of a Cochrane Review published in Issue 12, 2014 (<a href="./references#CD010682-bbs2-0057" title="MaguireMJ , WestonJ , SinghJ , MarsonAG . Antidepressants for people with epilepsy and depression. Cochrane Database of Systematic Reviews2014, Issue 12. Art. No: CD010682. [DOI: 10.1002/14651858.CD010682.pub2]">Maguire 2014</a>). </p> <section id="CD010682-sec-0010"> <h3 class="title" id="CD010682-sec-0010">Description of the condition</h3> <p>Depressive disorders are the most common psychiatric comorbidity in people with epilepsy (<a href="./references#CD010682-bbs2-0052" title="Tellez-ZentenoJF , PattenSB , JetteN , WilliamsJ , WiebeS . Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia2007;48(12):2336-44. [PMID: 17662062]">Tellez‐Zenteno 2007</a>), and they are the strongest predictor of poor quality of life (<a href="./references#CD010682-bbs2-0024" title="BoylanLS , FlintLA , LabovitzDL , JacksonSC , StarnerK , DevinskyO . Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology2004;62(2):258-61.">Boylan 2004</a>). Symptoms of depression include low mood, tiredness, and apathy. Sleep and cognitive functioning may also be affected. Depressive disorders occur in approximately one‐third of the people with epilepsy (<a href="./references#CD010682-bbs2-0023" title="BakerG , JacobyA , ChadwickD . The associations of psychopathology in epilepsy: a community study. Epilepsy Research1996;25:29-39.">Baker 1996</a>; <a href="./references#CD010682-bbs2-0038" title="IndacoA , CarrieriB , NaapiC , GentileS , StrianoS . Interictal depression in epilepsy. Epilepsy Research1992;12:45-50.">Indaco 1992</a>; <a href="./references#CD010682-bbs2-0039" title="JacobyA , BakerG , SteenN , PottsP , ChadwickD . The clinical course of epilepsy and its psychological correlates: finding from a U.K. community study. Epilepsia1996;37:148-61.">Jacoby 1996</a>; <a href="./references#CD010682-bbs2-0045" title="MendezM , CummingsJ , BensonD . Depression in epilepsy: significance and phenomenology. Archives of Neurology1986;43:766-70.">Mendez 1986</a>). These disorders are broadly divided into unipolar (depression only) and bipolar disorders (depression associated with mania or hypomania; (<a href="./references#CD010682-bbs2-0021" title="American Psychiatric Association. Diagnostic and Statistical Manual. 4th edition. Washington DC: American Psychiatric Association, 2000.">APA 2000</a>)). Depressive disorders in epilepsy may be mediated via the interplay of neurobiological, psychosocial, and iatrogenic factors (<a href="./references#CD010682-bbs2-0043" title="LambertM , RobertsonM . Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia1999;40(Suppl 10):s21-47.">Lambert 1999</a>). Depressive symptoms or episodes may occur inter‐ictally (i.e. they appear unrelated to seizures) or peri‐ictally (preceding, during, or following seizures). This is an important distinction, as a person may require modification of his or her antiepileptic drug regimen, commencement of antidepressant drug therapy, or both. In some people, the depressive symptoms may follow a significant period of seizure remission in previously uncontrolled epilepsy, thought to occur via neuro‐biochemical changes, and termed 'forced normalisation' (<a href="./references#CD010682-bbs2-0053" title="TrimbleMR . New antiepileptic drugs and psychopathology. Neuropsychobiology1998;38(3):149-51. [PMID: 9778603]">Trimble 1998</a>). Studies examining clinical predictors of risk for depression in people with epilepsy have produced inconsistent results (<a href="./references#CD010682-bbs2-0044" title="LinJJ , MulaM , HermannBP . Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet2012;380(9848):1180-92. [PMID: 23021287]">Lin 2012</a>). There is a perceived greater risk of depression in people with temporal lobe epilepsy, although elevated rates of depression have been found in generalised and extra‐temporal focal epilepsy (<a href="./references#CD010682-bbs2-0019" title="AdamsSJ , O'BrienTJ , LloydJ , KilpatrickCJ , SalzbergMR , VelakoulisD . Neuropsychiatric morbidity in focal epilepsy. British Journal of Psychiatry2008;192(6):464-9. [PMID: 18515901]">Adams 2008</a>). Epilepsy‐related factors as predictors of risk for depression are inconsistent. Psychosocial factors, such as life stress, coping style, social support, perceived stigma, and personality are more consistent predictors of depression in people with epilepsy (<a href="./references#CD010682-bbs2-0031" title="HermannBP , SeidenbergM , BellB . Psychiatric comorbidity in chronic epilepsy: identification, consequences, and treatment of major depression. Epilepsia2000;41(Suppl 2):S31-41. [PMID: 10885738]">Hermann 2000</a>). </p> <p>In 2008, the Food and Drug Administration issued a health alert about an increased risk of suicidal ideation in people taking antiepileptic drugs (<a href="./references#CD010682-bbs2-0034" title="HesdorfferDC , KannerAM . The FDA alert on suicidality and antiepileptic drugs: fire or false alarm?Epilepsia2009;50(5):978-86. [PMID: 19496806]">Hesdorffer 2009</a>). This alert was based on a meta‐analysis of approximately 28,000 participants who had participated in randomised controlled trials (RCTs) investigating 11 antiepileptic drugs. There were four completed suicides, all of whom had taken antiepileptic drugs, compared to no suicides in the placebo groups (odds ratio (OR) 1.8; 95% confidence interval (CI) 1.24 to 2.66). Since this alert, a number of observational studies have investigated the association, reporting conflicting results, and the International League Against Epilepsy (ILAE) Commission on Neuropsychobiology a has published a consensus statement on the risk of suicide with antiepileptic drugs (<a href="./references#CD010682-bbs2-0047" title="MulaM , KannerAM , SchmitzB , SchachterS . Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia2013;54(1):199-203. [PMID: 22994856]">Mula 2013</a>). Whilst the exact risk of suicide with antiepileptic drugs is unknown, depression, as a treatment emergent adverse effect, is associated with some antiepileptic drugs (GABAergic antiepileptic drugs: benzodiazepines, vigabatrin, gabapentin; and also topiramate, levetiracetam, and zonisamide; (<a href="./references#CD010682-bbs2-0046" title="MulaM , SchmitzB . Depression in epilepsy: mechanisms and therapeutic approach. Therapeutic Advances in Neurological Disorders2009;2(5):337-44. [PMID: 21180624]">Mula 2009</a>)). Other antiepileptic drugs appear to have mood‐stabilising properties (valproic acid, lamotrigine, carbamazepine, oxcarbazepine), which may benefit people with epilepsy and depression. Enzyme‐inducing antiepileptic drugs (i.e. carbamazepine) may lower plasma levels of antidepressants, thus impacting on their effectiveness. </p> <p>Case control studies have shown that participants with depression have a two‐ to seven‐fold higher risk of developing epilepsy, implying a bi‐directional relationship (<a href="./references#CD010682-bbs2-0032" title="HesdorfferDC , HauserWA , AnnegersJF , CascinoG . Major depression is a risk factor for seizures in older adults. Annals of Neurology2000;47(2):246-9.">Hesdorffer 2000</a>; <a href="./references#CD010682-bbs2-0033" title="HesdorfferDC , HauserWA , OlafssonE , LudvigssonP , KjartanssonO . Depression and suicide attempt as risk factors for incident unprovoked seizures. Annals of Neurology2006;59(1):35-41. [PMID: 16217743]">Hesdorffer 2006</a>; <a href="./references#CD010682-bbs2-0035" title="HesdorfferDC , IshiharaL , MynepalliL , WebbDJ , WeilJ , HauserWA . Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Annals of Neurology2012;72(2):184-91. [PMID: 22887468]">Hesdorffer 2012</a>). A number of factors may explain this, for example shared pathophysiology involving disturbances in several key neurotransmitter systems (<a href="./references#CD010682-bbs2-0022" title="BagdyG , KecskemetiV , RibaP , JakusR . Serotonin and epilepsy. Journal of Neurochemistry2007;100(4):857-73. [PMID: 17212700]">Bagdy 2007</a>), structural lesions (frontal lobe tumours), or a genetic susceptibility. However, there is also the possibility that the use of antidepressants may trigger seizures. This is a common concern for healthcare professionals, and may influence their decisions to start antidepressant treatment (<a href="./references#CD010682-bbs2-0025" title="Cotterman-HartS . Depression in epilepsy: why aren't we treating?Epilepsy &amp; Behavior2010;19(3):419-21. [PMID: 20851689]">Cotterman‐Hart 2010</a>). </p> </section> <section id="CD010682-sec-0011"> <h3 class="title" id="CD010682-sec-0011">Description of the intervention</h3> <p>Antidepressants are a heterogeneous class of drugs that have been the mainstay of pharmacological treatment for depressive disorders. There are 10 classes of antidepressants used to treat depressive disorders, with 60% to 70% of depressive episodes responding to current treatment (<a href="./references#CD010682-bbs2-0041" title="KlermanG . Treatment of recurrent unipolar major depressive disorder. Commentary on the Pittsburgh study. Archives of General Psychiatry1990;47(12):1158-61.">Klerman 1990</a>; <a href="./references#CD010682-bbs2-0049" title="SackeimHA , RooseSP , LavoriPW . Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD). Biological Psychiatry2006;59(6):483-92. [PMID: 16517241]">Sackeim 2006</a>). These are: </p> <p> <ol id="CD010682-list-0001"> <li> <p>tricyclic antidepressants;</p> </li> <li> <p>selective serotonin reuptake inhibitors;</p> </li> <li> <p>serotonin‐norepinephrine reuptake inhibitors;</p> </li> <li> <p>monoamine oxidase inhibitors;</p> </li> <li> <p>serotonin/antagonist reuptake inhibitors (i.e. trazodone);</p> </li> <li> <p>dopamine and norepinephrine reuptake inhibitors (i.e. bupropion);</p> </li> <li> <p>a‐2 antagonists (i.e. mirtazapine);</p> </li> <li> <p>norepinephrine reuptake inhibitors (i.e. reboxetine);</p> </li> <li> <p>selective serotonin reuptake enhancers (i.e. tianeptine); and</p> </li> <li> <p>serotonin 5HT₂C receptor antagonists (i.e. agomelatine).</p> </li> </ol> </p> <p>These drugs work by targeting serotonergic, or noradrenergic, or dopaminergic neurotransmission, or a combination, with the aim of increasing their synaptic concentrations (<a href="./references#CD010682-bbs2-0050" title="StahlSM . Blue genes and the mechanism of action of antidepressants. Journal of Clinical Psychiatry2000;61(3):164-5. [PMID: 10817098]">Stahl 2000</a>). Glutamate antagonists represent a novel class of drug currently being tested in refractory depression (<a href="./references#CD010682-bbs2-0055" title="Zarate CA Jr, SinghJB , CarlsonPJ , BrutscheNE , AmeliR , LuckenbaughDA , et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry2006;63(8):856-64. [PMID: 16894061]">Zarate 2006</a>). </p> <p>The risk of seizures with antidepressants was reported in early studies of the first generation antidepressants, notably tricyclic antidepressants (<a href="./references#CD010682-bbs2-0048" title="PreskornSH , FastGA . Tricyclic antidepressant-induced seizures and plasma drug concentration. Journal of Clinical Psychiatry1992;53(5):160-2. [PMID: 1592842]">Preskorn 1992</a>; <a href="./references#CD010682-bbs2-0054" title="WroblewskiBA , McColganK , SmithK , WhyteJ , SingerWD . The incidence of seizures during tricyclic antidepressant drug treatment in a brain-injured population. Journal of Clinical Psychopharmacology1990;10(2):124-8. [PMID: 2341586]">Wroblewski 1990</a>). <a href="./references#CD010682-bbs2-0020" title="AlperK , SchwartzKA , KoltsRL , KhanA . Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biological Psychiatry2007;62(4):345-54. [PMID: 17223086]">Alper 2007</a> reviewed the incidence of seizures in 75,000 non‐epileptic participants in phase II and phase III trials of antidepressant treatment. They reported lower incidence rates of seizures in those randomised to an antidepressant versus placebo (standardised incidence ratio 0.48; 95% CI 0.36 to 0.61). <a href="./references#CD010682-bbs2-0026" title="CouplandC , DhimanP , MorrissR , ArthurA , BartonG , Hippisley-CoxJ . Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ2011;343:d4551. [PMID: 21810886]">Coupland 2011</a> examined 60,746 primary care participants aged 65 and over, treated for depression with antidepressants, between 1996 and 2007, and showed increased risks of epilepsy or seizures for selective serotonin reuptake inhibitors (hazard ratio (HR) 1.80; 95% CI 1.32 to 2.43), and other antidepressant classes (HR 2.20; 95% CI 1.46 to 3.30) versus tricyclic antidepressants. Venlafaxine was associated with the highest risk of seizures. </p> </section> <section id="CD010682-sec-0012"> <h3 class="title" id="CD010682-sec-0012">How the intervention might work</h3> <p>There appears to be a significant relationship between epilepsy and depression. From studies, it is emerging that they share common neurobiological substrates that involve hyperactivity of the hypothalamic pituitary adrenal axis, and the disturbance of different neurotransmitter systems, mainly serotonin and norepinephrine (<a href="./references#CD010682-bbs2-0027" title="Dell'ossoMC , CasertaA , BaroniS , NisitaC , MarazzitiD . The relationship between epilepsy and depression: an update. Current Medicinal Chemistry 2013 Mar 15 [Epub ahead of print]. [PMID: 23521673]">Dell'osso 2013</a>). The density of serotonin receptors is high in the mesial temporal and prefrontal areas (<a href="./references#CD010682-bbs2-0028" title="GilliamFG . Diagnosis and treatment of mood disorders in persons with epilepsy. Current Opinion in Neurology2005;18(2):129-33. [PMID: 15791142]">Gilliam 2005b</a>). In critical brain regions, such as the limbic system and prefrontal areas, enforced serotonergic circuits seem to be responsible for increasing seizure threshold (<a href="./references#CD010682-bbs2-0042" title="KondziellaD , AsztelyF . Don't be afraid to treat depression in patients with epilepsy!Acta Neurologica Scandinavica2009;119(2):75-80. [PMID: 18759799]">Kondziella 2009</a>). </p> <p>Antidepressants of the selective serotonin reuptake inhibitor family have been reported to be safe in treating depression in people with epilepsy, and to possess antiepileptic properties in animal models of epilepsy (<a href="./references#CD010682-bbs2-0030" title="HamidH , KannerAM . Should antidepressant drugs of the selective serotonin reuptake inhibitor family be tested as antiepileptic drugs?Epilepsy &amp; Behavior2013;26(3):261-5. [PMID: 23395350]">Hamid 2013</a>). Based on clinical data, it has been suggested that selective serotonin reuptake inhibitors can decrease the seizure frequency in refractory epilepsy (<a href="./references#CD010682-bbs2-0042" title="KondziellaD , AsztelyF . Don't be afraid to treat depression in patients with epilepsy!Acta Neurologica Scandinavica2009;119(2):75-80. [PMID: 18759799]">Kondziella 2009</a>). This is believed to be due to the increase in the concentration of serotonin. The study shows that the concentration of endogenous serotonin (5‐HT) and the activity of its receptor subtypes, 5–HT(1A), 5‐HT(2C), 5‐HT(3), and 5–HT(7), play a significant role in the pathogenesis of epilepsies (<a href="./references#CD010682-bbs2-0022" title="BagdyG , KecskemetiV , RibaP , JakusR . Serotonin and epilepsy. Journal of Neurochemistry2007;100(4):857-73. [PMID: 17212700]">Bagdy 2007</a>). Therefore, medications with serotonin agonist and antagonist properties can play a significant role in the pathogenesis of epilepsies. </p> </section> <section id="CD010682-sec-0013"> <h3 class="title" id="CD010682-sec-0013">Why it is important to do this review</h3> <p>Depression is common in people with epilepsy, and has a significant negative impact on quality of life (<a href="./references#CD010682-bbs2-0028" title="GilliamFG . Diagnosis and treatment of mood disorders in persons with epilepsy. Current Opinion in Neurology2005;18(2):129-33. [PMID: 15791142]">Gilliam 2005b</a>; <a href="./references#CD010682-bbs2-0042" title="KondziellaD , AsztelyF . Don't be afraid to treat depression in patients with epilepsy!Acta Neurologica Scandinavica2009;119(2):75-80. [PMID: 18759799]">Kondziella 2009</a>). There is concern that they may not be receiving appropriate treatment for their depression because of uncertainty around which antidepressant, or class, works best, and the perceived risk of exacerbating seizures. This review aims to address these issues, and to inform clinical practice and future research. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010682-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010682-sec-0014"></div> <p>To evaluate the efficacy and safety of antidepressants in treating depressive symptoms and the effect on seizure recurrence, in people with epilepsy and depression. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010682-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010682-sec-0015"></div> <section id="CD010682-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010682-sec-0017"> <h4 class="title">Types of studies</h4> <p> <ul id="CD010682-list-0002"> <li> <p>Randomised controlled trials (RCTs)</p> </li> <li> <p>Prospective non‐randomised cohort controlled and uncontrolled studies (NRSI; with a control group including participants acting as their own control group (i.e. before‐after studies)). </p> <ul id="CD010682-list-0003"> <li> <p>We considered prospective non‐randomised cohort studies in this review because of the known delayed effect of antidepressants on depressive symptoms, which may not be effectively detected in short‐term randomised trials. Similarly, prospective non‐randomised studies are more likely to recruit populations of participants who better reflect clinical practice, since depression can affect any person with epilepsy. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD010682-sec-0018"> <h4 class="title">Types of participants</h4> <p>We considered participants who satisfied all of the following criteria:</p> <p> <ul id="CD010682-list-0004"> <li> <p>any age;</p> </li> <li> <p>diagnosis of epilepsy (any type);</p> </li> <li> <p>treated with antidepressants for co‐existing depression (including participants with major depressive disorder, adjustment disorder, and dysthymic disorder), based on standardised criteria, according to participant scores on validated tools, or both (e.g. Hamilton Rating Scale for Depression). </p> </li> </ul> </p> </section> <section id="CD010682-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD010682-list-0005"> <li> <p>Intervention group: participants who received an antidepressant drug in addition to an existing antiepileptic drug regimen </p> </li> <li> <p>Control group(s): participants who received a placebo, comparative antidepressant, psychotherapy, or no treatment in addition to an existing antiepileptic drug regimen </p> </li> </ul> </p> </section> <section id="CD010682-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD010682-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010682-list-0006"> <li> <p>Depression scores</p> <ul id="CD010682-list-0007"> <li> <p>The proportion of participants with a greater than 50% improvement in depressive symptoms (defined as a 'response') compared to baseline </p> </li> <li> <p>Mean difference in depression scores following treatment (compared to baseline or between‐group comparison) </p> </li> <li> <p>The proportion of participants achieving complete remission of depressive symptoms</p> </li> </ul> </li> </ul> </p> <p>If the data allowed, we planned to analyse outcomes at ≤ 12 weeks (short‐term), 13 to 26 weeks (medium‐term), and ≥ 26 weeks (long‐term); however, we were unable to perform these analyses. </p> <p> <ul id="CD010682-list-0008"> <li> <p>Change in seizure frequency</p> <ul id="CD010682-list-0009"> <li> <p>The mean difference in seizure frequency</p> </li> <li> <p>The proportion of participants with a seizure recurrence</p> </li> <li> <p>The proportion of participants with an episode of status epilepticus</p> </li> </ul> </li> </ul> </p> </section> <section id="CD010682-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010682-list-0010"> <li> <p>Withdrawals</p> <ul id="CD010682-list-0011"> <li> <p>For specific reasons</p> </li> <li> <p>For any reasons</p> </li> </ul> </li> <li> <p>Global state</p> <ul id="CD010682-list-0012"> <li> <p>Clinically important change in global state (as defined by the individual studies)</p> </li> <li> <p>Relapse (as defined by the individual studies)</p> </li> </ul> </li> <li> <p>Mental state</p> <ul id="CD010682-list-0013"> <li> <p>Clinically important change in general mental state score</p> </li> <li> <p>General mental state score (average and end point)</p> </li> <li> <p>Clinically important change in specific symptoms (sleep, anhedonia, suicidal ideas)</p> </li> <li> <p>Specific symptom score (average and end point)</p> </li> </ul> </li> <li> <p>General functioning</p> <ul id="CD010682-list-0014"> <li> <p>Clinically important change in general functioning</p> </li> <li> <p>General functioning score (average and end point)</p> </li> </ul> </li> <li> <p>Cognitive functioning</p> <ul id="CD010682-list-0015"> <li> <p>Clinically important change in overall cognitive functioning</p> </li> <li> <p>Overall cognitive functioning score (end point and average)</p> </li> <li> <p>Clinically important change in specific cognitive functioning (attention, concentration, memory, language, executive functioning) </p> </li> <li> <p>Specific cognitive score (average and end point)</p> </li> </ul> </li> <li> <p>Quality of life</p> <ul id="CD010682-list-0016"> <li> <p>Clinically important change in quality of life</p> </li> <li> <p>Any change in quality of life score (average and end point)</p> </li> </ul> </li> <li> <p>Behaviour</p> <ul id="CD010682-list-0017"> <li> <p>Clinically important change in general behaviour</p> </li> <li> <p>Any important change in general behaviour (average and end point)</p> </li> <li> <p>Clinically important change in specific aspects of behaviour</p> </li> <li> <p>Any important change in specific aspects of behaviour score (average and end point)</p> </li> </ul> </li> <li> <p>Adverse effects</p> <ul id="CD010682-list-0018"> <li> <p>Death</p> </li> <li> <p>Any non‐serious general adverse effects (e.g. gastrointestinal effects, anorexia, dizziness, dry mouth, insomnia, sexual dysfunction, hypotension) </p> </li> <li> <p>Any serious, specific adverse effects (hypersensitivity reaction)</p> </li> <li> <p>Any change in general adverse effect score (average and end point)</p> </li> <li> <p>Clinically important change in specific adverse effects</p> </li> <li> <p>Any change in specific adverse effects score (average and end point)</p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD010682-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010682-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We ran searches for the original review in March 2013. We ran subsequent searches in May 2014, October 2016, July 2018, and October 2019. For the latest update, we searched the following databases. </p> <p> <ol id="CD010682-list-0019"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), in CRS Web (searched 1 February 2021), using the search strategy shown in <a href="./appendices#CD010682-sec-0095">Appendix 1</a>; </p> </li> <li> <p>MEDLINE Ovid (1946 to 29 January 2021), using the search strategy shown in <a href="./appendices#CD010682-sec-0096">Appendix 2</a>; </p> </li> <li> <p>SCOPUS (1823 to 1 February 2021), using the search strategy shown in <a href="./appendices#CD010682-sec-0097">Appendix 3</a>; </p> </li> <li> <p>PsycINFO EBSCOhost (1887 to 1 February 2021), using the search strategy shown in <a href="./appendices#CD010682-sec-0098">Appendix 4</a>; </p> </li> <li> <p><a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> (searched 1 February 2021), using the search strategy shown in <a href="./appendices#CD010682-sec-0099">Appendix 5</a>; </p> </li> <li> <p><a href="http://apps.who.int/trialsearch/" target="_blank">WHO International Clinical Trials Registry Platform</a> (ICTRP; searched 22 October 2019), using the search strategy shown in <a href="./appendices#CD010682-sec-0100">Appendix 6</a>. We were unable to update this search because the ICTRP website was inaccessible. </p> </li> </ol> </p> <p>CRS Web includes randomised or quasi‐randomised, controlled trials from the Specialized Registers of Cochrane Review Groups, including Epilepsy, CENTRAL, PubMed, Embase, ClinicalTrials.gov, and ICTRP. </p> <p>There were no language restrictions.</p> </section> <section id="CD010682-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of retrieved studies for additional reports of relevant studies. </p> <p>We also contacted lead study authors for any relevant unpublished material.</p> <p>We identified duplicate studies by screening reports according to title, authors’ names, location, and medical institute, omitting any duplicated studies. </p> <p>We identified any grey literature studies published in the last five years by searching:<br/>1. Zetoc database;<br/>2. ISI Proceedings;<br/>3. International Bureau for Epilepsy (IBE) congress proceedings database;<br/>4. International League Against Epilepsy (ILAE) congress proceedings database;<br/>5. Abstract books of symposia and congresses, meeting abstracts, and research reports </p> </section> </section> <section id="CD010682-sec-0026"> <h3 class="title" id="CD010682-sec-0026">Data collection and analysis</h3> <section id="CD010682-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two authors (MM, SN) independently assessed all citations generated from the searches for inclusion. Where disputes arose, we acquired the full report for more detailed scrutiny. </p> </section> <section id="CD010682-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two authors (MM, SJN) undertook separate data extraction for each included study. We then cross‐checked the data extraction. We extracted data using pre‐standardised data extraction forms. We discussed any disagreement, documented decisions, and if necessary, contacted trialists for clarification. </p> <p>We extracted the following information from the included studies.</p> <section id="CD010682-sec-0029"> <h5 class="title">Methodological and trial design</h5> <p> <ul id="CD010682-list-0020"> <li> <p>Year of publication</p> </li> <li> <p>Number of study centres</p> </li> <li> <p>Language</p> </li> <li> <p>Industry funding</p> </li> <li> <p>Study design (RCT, prospective cohort study, retrospective cohort study)</p> </li> <li> <p>Blinding</p> </li> <li> <p>Type of control group (placebo, comparative antidepressant, no treatment)</p> </li> <li> <p>Sample size</p> </li> <li> <p>Follow‐up period</p> </li> <li> <p>Class of antidepressant as intervention</p> </li> <li> <p>Dose range of intervention</p> </li> <li> <p>Inclusion and exclusion criteria</p> </li> </ul> </p> </section> <section id="CD010682-sec-0030"> <h5 class="title">Participant demographic information</h5> <p> <ul id="CD010682-list-0021"> <li> <p>Age range</p> </li> <li> <p>Number of male/female participants</p> </li> <li> <p>Duration of epilepsy</p> </li> <li> <p>Previous number of antiepileptic drugs</p> </li> <li> <p>Epilepsy type (focal, generalised, unclassified)</p> </li> <li> <p>Location of epilepsy (temporal, extra‐temporal)</p> </li> <li> <p>Baseline mean depression score or severity</p> </li> <li> <p>Baseline mean seizure frequency/month</p> </li> </ul> </p> </section> <section id="CD010682-sec-0031"> <h5 class="title">Outcomes</h5> <p> <ul id="CD010682-list-0022"> <li> <p>The number of participants experiencing each outcome recorded per treatment group</p> </li> <li> <p>Number of dropouts</p> </li> </ul> </p> </section> </section> <section id="CD010682-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SJN, MJM) independently assessed the risk of bias for the included studies. </p> <p>Due to the non‐randomised design of some studies, we assessed risk of bias for non‐randomised studies using the ROBINS‐I tool (<a href="https://archie.cochrane.org/sections/documents/view?version=z2003301247036088213586935834807&amp;format=JATS#REF-Sterne-2016" target="_blank">Sterne 2016</a>). This tool considers seven domains of bias: two domains of bias pre‐intervention (bias due to confounding and bias in selection of participants into the study); one domain of bias at intervention (bias in the measurement of interventions); and four domains of bias post‐intervention (bias due to departures from intended interventions, bias due to missing data, bias in measurement of outcomes, and bias in selection of the reported result). We planned to perform a separate 'Risk of bias' assessment for each outcome of interest in the study. </p> <p>Important confounders of interest in this Cochrane Review included:</p> <p> <ol id="CD010682-list-0023"> <li> <p>mean age;</p> </li> <li> <p>epilepsy type (focal or generalised);</p> </li> <li> <p>mean duration of epilepsy;</p> </li> <li> <p>location of epilepsy;</p> </li> <li> <p>mean baseline seizure frequency;</p> </li> <li> <p>mean baseline depression score.</p> </li> </ol> </p> <p>Each domain of bias contained signalling questions to facilitate judgements of risk of bias. The response options for the signalling questions were: yes; probably yes; probably no; no; and no information. We specified the signalling questions for each domain in <a href="./appendices#CD010682-sec-0101">Appendix 7</a>. </p> <p>The 'Risk of bias' judgement options for each domain were:</p> <p> <ol id="CD010682-list-0024"> <li> <p>low risk of bias: the study is comparable to a well‐performed randomised trial with regard to this domain; </p> </li> <li> <p>moderate risk of bias: the study is sound for a non‐randomised study with regard to this domain, but cannot be considered comparable to a well‐performed randomised trial; </p> </li> <li> <p>serious risk of bias: the study has some important problems in this domain;</p> </li> <li> <p>critical risk of bias: the study is too problematic in this domain to provide any useful evidence on the effects of the intervention; </p> </li> <li> <p>no information on which to base a judgement about risk of bias for this domain.</p> </li> </ol> </p> <p>We presented guidance for an overall risk of bias for a study, based on outcomes from 'Risk of bias' judgements of each domain, in <a href="#CD010682-tbl-0007">Table 1</a>. </p> <div class="table" id="CD010682-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria for overall risk of bias judgements from ROBINS‐I</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk of bias judgement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Criteria based on seven risk of bias domains</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low risk of bias:</b> the study is comparable to a well‐performed randomised trial </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study is judged to be at low risk of bias for all domains</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate risk of bias:</b> the study appears to provide sound evidence for a non‐randomised study but cannot be considered comparable to a well‐performed randomised trial </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study is judged to be at low or moderate risk of bias for all domains</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious risk of bias:</b> the study has some important problems </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study is judged to be at serious risk of bias in at least 1 domain, but not at critical risk of bias in any domain </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Critical risk of bias:</b> the study is too problematic to provide any useful evidence on the effects of intervention </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study is judged to be at critical risk of bias in at least 1 domain</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No information</b> on which to base a judgement about risk of bias </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is no clear indication that the study is at serious or critical risk of bias, and there is a lack of information in 1 or more key domains of bias (a judgement is required for this) </p> </td> </tr> </tbody> </table> </div> <p>For RCTs, we assessed all domains of the Cochrane tool for assessing risk of bias (<a href="./references#CD010682-bbs2-0036" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We rated each of the following six domains as low, high, or unclear risk of bias: method of generating random sequence, allocation concealment, blinding methods, incomplete outcome data, selective outcome reporting, and other sources of bias. </p> <p>The two review authors resolved any discrepancies in the 'Risk of bias' judgements by discussion. </p> </section> <section id="CD010682-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes (50% or greater improvement in depressive symptoms, complete remission of depressive symptoms, and % treatment withdrawal), we presented results as risk ratios (RR) with 95% confidence interval (CI). To allow for multiple statistical testing, we presented RRs with 99% CIs for specific adverse events. </p> <p>For continuous outcomes (mean change in depression score), we presented results as mean differences (MD) or standardised mean differences (SMD) with 95% CIs. </p> </section> <section id="CD010682-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>Studies using a variety of depression measures created issues when we wanted to combine results in a meta‐analysis. Where appropriate, we used the SMD to allow for these variances. </p> </section> <section id="CD010682-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We sought missing statistics from studies through contact with the study authors. We sought reasons for missing data to determine whether the data were missing at random or not. We found no data missing at random. </p> </section> <section id="CD010682-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by comparing the distribution of important participant factors between studies (age, epilepsy type, duration of epilepsy, baseline depression score, baseline seizure frequency) and trial factors (study design, type of control group, antidepressant drug class, type of depression disorder). We assessed statistical heterogeneity by using the I² statistic. We considered an I² value of 75% or more indicated considerable heterogeneity, 50% to 90% indicated substantial heterogeneity, and 30% to 60% indicated moderate heterogeneity. If the I² value was 75% or more, we made an a priori decision not to carry out meta‐analysis; instead, we used a narrative form for the review, and discussed all comparisons according to the findings presented within the studies. We planned meta‐regression techniques, where possible, to investigate possible sources of heterogeneity, however, we were unable to investigate this within this review. </p> </section> <section id="CD010682-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD010682-sec-0038"> <h5 class="title">1. Protocol versus full study</h5> <p>We investigated outcome reporting bias using the ORBIT classification system, allocating studies a letter from A to I if we suspected the presence of selective outcome reporting bias (<a href="./references#CD010682-bbs2-0040" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. [PMID: 20156912]">Kirkham 2010</a>). </p> </section> <section id="CD010682-sec-0039"> <h5 class="title">2. Funnel plot</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD010682-bbs2-0037" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>; <a href="./references#CD010682-bbs2-0051" title="SterneJA , GavaghanD , EggerM . Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of Clinical Epidemiology2000;53(11):1119-29. [PMID: 11106885]">Sterne 2000</a>). Funnel plots can be used to investigate reporting biases, but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes for which there were 10 or fewer studies, or when all studies were of similar sizes. </p> </section> </section> <section id="CD010682-sec-0040"> <h4 class="title">Data synthesis</h4> <p>We synthesised data using the RR, the MD, or the SMD, depending on the measures used in both the controlled and uncontrolled studies. We carried out a sensitivity analysis to check for differences between a random‐effects model and fixed‐effect model in influencing conclusions. If differences between the models existed, we intended to report outcomes based on the random‐effects model, which incorporates an assumption that the different studies are estimating different, yet related, intervention effects. </p> <p>For controlled studies, we intended to carry out meta‐analysis using the Mantel‐Haenszel method for dichotomous outcomes, and the inverse variance method for continuous outcomes. For before‐after studies, we used the inverse variance methods for continuous outcomes in meta‐analysis. </p> <p>We did not combine data for outcomes measured in both randomised and non‐randomised studies. We reported combined data on outcomes for randomised and non‐randomised studies separately. </p> <p>We stratified each comparison by type of control group, study design, study characteristics, or a combination, to ensure appropriate combination of study data. </p> </section> <section id="CD010682-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where possible, we planned to stratify subgroup analysis by antidepressant drug class, epilepsy type, and age. For investigation of heterogeneity, please see <a href="#CD010682-sec-0036">Assessment of heterogeneity</a>. </p> </section> <section id="CD010682-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>We intended to carry out sensitivity analysis if peculiarities in study quality were found (<a href="#CD010682-sec-0032">Assessment of risk of bias in included studies</a>). We planned to report the analysis for all studies, and then compare this to an analysis of only studies at low risk of bias. However, as we could not combine RCTs in meta‐analysis, and we judged all NRSIs to be at serious risk of bias, we did not perform any sensitivity analyses. </p> </section> <section id="CD010682-sec-0043"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We made an overall summary judgement of risk of bias for each study per outcome, followed by an overall judgement per outcome across studies. We had planned to incorporate the 'Risk of bias' judgements into the analysis using a sensitivity analysis, so that a secondary analysis of the data included only studies rated as low risk of bias. However, we were unable to do this due to the small amount of studies and lack of data. We presented both results in the <a href="./full#CD010682-sec-0044">Results</a> section of the review. Where applicable, we created 'Summary of findings' tables for outcomes, and graded each outcome using the GRADE approach (<a href="./references#CD010682-bbs2-0029" title="GuyattGH , OxmanAD , VistG , KunzR , Falck-YtterY , Alonso-CoelloP , et al, for the GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6.">Guyatt 2008</a>). Outcomes reported in 'Summary of findings' tables include: depression scores, seizure frequency, withdrawals, cognitive functioning, quality of life, and adverse effects. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010682-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010682-sec-0044"></div> <section id="CD010682-sec-0045"> <h3 class="title">Description of studies</h3> <section id="CD010682-sec-0046"> <h4 class="title">Results of the search</h4> <p>We identified 18 potentially eligible studies. We made our final assessment of eligibility by checking the full text of the reports. <a href="#CD010682-fig-0001">Figure 1</a> outlines the flow diagram of search results, eligible records, and study exclusions. </p> <div class="figure" id="CD010682-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD010682-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>We excluded six studies; three studies did not meet the inclusion criteria, and a further three studies met the inclusion criteria but did not report any results for any of the primary and secondary outcomes. We attempted to contact trial authors of these three studies, but received no response. </p> <p>Two studies are currently ongoing (<a href="./references#CD010682-bbs2-0017" title="EUCTR2017-000990-35-IT. Effects of the antidepressive therapy with agomelatin and escitalopram in people with depression and epilepsy [Effects of antidepressant treatment with agomelatine on patients affected by depression and epilepsy. A double blind randomized study with active control (escitalopram) with parallel groups]. www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000990-35 (first posted 6 February 2019). ">EUCTR2017‐000990‐35‐IT</a>; <a href="./references#CD010682-bbs2-0018" title="EUCTR2018-003464-32-HU. Effect of mirtazapine on seizure frequency in epileptic patients with vagal nerve stimulation device. www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003464-32 (first posted 5 November 2019). ">EUCTR2018‐003464‐32‐HU</a>). </p> </section> <section id="CD010682-sec-0047"> <h4 class="title">Included studies</h4> <p>Of the ten remaining studies, four were randomised controlled trials and six non‐randomised prospective cohort studies examining the effect of antidepressant drugs. </p> <p>We found four randomised trials of antidepressant versus cognitive behavioural therapy, active drug control, placebo, or no treatment, which reported on the primary efficacy outcome (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>; <a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>; <a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a>; <a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a>). One was a multi‐centre study (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>), the rest were single centre. A total of 313 participants were randomised in these studies; 199 participants had focal epilepsy. The remaining six non‐randomised prospective cohort studies reported on a total of 313 participants treated with an antidepressant, reported on the primary efficacy outcome (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>; <a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>; <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>; <a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a>). Two hundred and ninety seven participants had focal epilepsy; 290 were treated with a selective serotonin reuptake inhibitor, and seven with cognitive behavioural therapy. </p> <p>Seven studies reported outcomes for adults participants only; three studies reported outcomes for adults and children (<a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>; <a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a>; <a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a>). </p> <p>Eight studies included participants with focal onset epilepsy; two studies included participants with generalised onset epilepsy (<a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>; <a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a>). In all trials, there was a larger or equal number of female participants. </p> <p>Six studies evaluated the efficacy of selective serotonin reuptake inhibitors (citalopram, sertraline, fluoxetine) versus no treatment, a tricyclic antidepressant (doxepin), a norepinephrine reuptake inhibitor (reboxetine), or an alpha‐2 antagonists (mirtazapine; (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>; <a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>; <a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>; <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>; <a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a>)). One study evaluated a serotonin‐norepinephrine reuptake inhibitor (venlafaxine) versus no treatment (<a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a>); another, a tricyclic antidepressant (amitriptyline) versus dopamine and a norepinephrine reuptake inhibitor (nomifensine; (<a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a>)). Two studies evaluated the efficacy of selective serotonin reuptake inhibitors (sertraline, citalopram) versus cognitive behavioural therapy (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>). </p> <p>Five studies used the Hamilton Rating Scale for Depression (HAMD; (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>; <a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>; <a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a>; <a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a>)). Two studies used both the Mini International Neuropsychiatric Interview (MINI) and Beck Depression Inventory (BDI; (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>)). One study used the Montgomery‐Åsberg Depression Rating Scale (MADRS; <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>)), one study used the Kiddie SADS depression score (<a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a>), and one study did not report the use of a specific depression rating scale (<a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>). </p> <section id="CD010682-sec-0048"> <h5 class="title">Randomised Controlled Trials</h5> <p><a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a> was a published multi‐centre, randomised controlled trial, conducted in the USA, with 140 participants. Participants had a mean age of 39.6 years, 77 participants were female, and 56% of participants had focal epilepsy. Participants were randomised to receive sertraline (50 mg to 200 mg/day) or cognitive behavioural therapy (CBT). Changes in the MINI score, CES‐D, Beck Depression Inventory (BDI), QOLIE‐89 score, and adverse event profile (AEP) scores were compared from baseline to 8 weeks and 16 weeks. Changes in monthly seizure rates were compared from a retrospective 3‐month baseline, to 8 weeks and 16 weeks. Recurrence of a GTCS during the study was compared in those subjects who had not had a GTCS in a retrospective six‐month period prior to study enrolment. Of the 140 participants, 42 did not complete treatment as assigned, 15 of whom were lost to follow‐up. All participants were included in the reported analysis. </p> <p><a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a> was a published, single‐centre, randomised controlled trial, conducted in China, with 67 participants. Forty‐two participants had generalised onset epilepsy. The participants were aged between 14 and 62 years, and 35 participants were female. Thirty‐three participants were randomised to paroxetine, which was started at 10 mg/day and titrated up to 40 mg/day, depending on response. Thirty‐four participants were randomised to doxepin, which was started at 25 mg/day and titrated up, according to response (mean dose 100 mg/day). The Hamilton Rating Scale for Depression (HAMD) score was measured at eight weeks and compared to the baseline score. Seizure frequency was not assessed. Three participants in the doxepin treatment arm dropped out and were not included in the primary analysis. </p> <p><a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a> was a published, single‐centre, randomised, placebo‐controlled trial, conducted in the UK, with 42 participants. The majority had focal onset epilepsy. The participants were aged between 18 and 60 years, and 26 were female. Participants were randomised to amitriptyline, nomifensine, or placebo. All treatment arms completed a six‐week phase, and then both active treatment arms continued the study for a further six weeks. At 12 weeks of treatment, Hamilton Rating Scale for Depression (HAMD) scores were compared to baseline. Three participants withdrew from the study. Twenty‐eight participants in the active treatment arms were included in the primary outcome analysis at 12 weeks. </p> <p><a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a> was a published, single‐centre, randomised trial of venlafaxine versus no treatment, conducted in China, with 64 participants. The participants were aged between 7 and 60 years. Thirty‐two participants were randomised to venlafaxine 25 mg/day to 75 mg/day; 32 participants received no treatment. Depression scores were measured at eight weeks of treatment, using the Hamilton Rating Scale for Depression (HAMD), and compared to baseline. Seizure frequency was not reported. There were no dropouts, and all participants were included in the primary outcome analysis. </p> </section> <section id="CD010682-sec-0049"> <h5 class="title">Non‐Randomised Prospective Cohort Studies</h5> <p><a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a> was a published, single‐centre, prospective cohort study, conducted in the Czech Republic, with 43 participants. Two‐thirds of the participants had focal epilepsy. Participants were between the ages of 12 and 49 years, and 35 participants were female. . All participants received citalopram (mean daily dose 22.6 mg ± 8.3 mg) for eight weeks. At four and eight weeks, Hamilton Rating Scale for Depression (HAMD) depression scores and seizure frequencies were measured and compared to an unspecified baseline period. There were no treatment withdrawals; all 43 participants were included in the reported analysis. </p> <p><a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a> was a published, single‐centre, prospective cohort study, conducted in the USA, with 100 participants. Participants were aged between 6 and 62 years, 95% had focal onset epilepsy, and 49 participants were female. All participants received sertraline (25 mg/day to 200 mg/day; mean dose of 108 mg/day ± 56.9 mg/day), and were followed up for 0.2 to 38 months. Monthly seizure frequencies were compared during the treatment period, and to a 3‐ and 12‐month retrospective baseline period. No changes in depression scores were reported. Of the 100 participants, 18 withdrew from the study. All participants were included in the primary efficacy analysis. </p> <p><a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a> was a published, single‐centre, prospective cohort study, conducted in Germany, with 75 participants. All had focal onset epilepsy (temporal lobe). The participants were aged between 19 and 68 years, and 45 participants were female. Twenty‐seven participants received mirtazepine (mean daily dose 32.2 mg), 33 participants received citalopram (mean daily dose 24.2 mg), and 15 participants received reboxetine (mean daily dose 6.9 mg). Changes in Hamilton Rating Scale for Depression (HAMD) depression scores and treatment responders were measured at four weeks and 20 to 30 weeks, and compared to baseline scores. Changes in seizure frequency were not measured. Forty‐two participants dropped out; eight dropped out between baseline and week four, 34 dropped out between week four and weeks 20 to 30. The last observation carried forward method was used, and all participants were included in the primary efficacy outcomes. </p> <p><a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a> was a published, single‐centre, prospective study, conducted in Mexico, with 15 participants. All participants had temporal lobe epilepsy, and 11 participants were female. Seven participants received 12 sessions of cognitive behavioural therapy, and 8 participants received an SSRI (either sertraline (200 mg/day to 400 mg/day or citalopram 20 mg/day) over a 12‐week period. The Beck Depression Inventory (BDI) score, HADS score, QOLIE‐31, MINI, and monthly seizure frequency were compared at 6 and 12 weeks to baseline scores. There were two dropouts in the CBT group, and one participant was lost to follow‐up in the SSRI group. All participants were included in the reported analyses. </p> <p><a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a> was a published, multi‐centre, prospective cohort study, conducted in Italy, with 45 participants. Forty‐four participants had focal onset epilepsy. The participants had a mean age of 42.7 years, and 31 were female. All participants received citalopram for four months. Montgomery–Åsberg Depression Rating Scale (MADRS) depression scores and seizure frequency were measured at two and four months on citalopram, and compared to baseline measures. Six participants withdrew from the study and were omitted from the primary outcome analysis. </p> <p><a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a> was a published, single‐centre, prospective cohort study, conducted in Brazil, with 36 participants with focal onset epilepsy. The participants were aged between six and 18 years, and 19 were female. Twenty‐eight participants received sertraline (50 mg/day to 200 mg/day), and eight participants received fluoxetine (20 mg/day to 80 mg/day) for 12 to 78 months. Change in Kiddie SADS score was measured during the treatment phase, and compared to a six‐month baseline score. Seizure exacerbation was also observed during the treatment phase. One participant dropped out of the study. All participants were included in the primary outcome analysis. </p> </section> </section> <section id="CD010682-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We excluded six studies. One was a clinical trial comparing escitalopram and no treatment (<a href="./references#CD010682-bbs2-0015" title="NCT01244724. Lexapro for major depression in patients with epilepsy. clinicaltrials.gov/show/NCT01244724 (first posted 19 November 2010). ">NCT01244724</a>). This trial was terminated early due to problems with recruitment, and there were no available published data. The second study was a very small pilot trial comparing escitalopram and referral to psychiatry (<a href="./references#CD010682-bbs2-0016" title="NCT03464383. Anxiety and depression in epilepsy: a treatment study [Anxiety and depression in epilepsy: a pilot epileptologist-driven treatment study]. clinicaltrials.gov/ct2/show/record/NCT03464383 (first received 7 March 2018). ">NCT03464383</a>). Only three participants were recruited to each study arm, and limited outcome data were available.  The third study reported on a small case series of participants with epilepsy, who were taking a combined tricyclic antidepressant and SSRI for depression, and did not fulfil the inclusion criteria (<a href="./references#CD010682-bbs2-0011" title="BlumerD . Antidepressant and double antidepressant treatment for the affective disorder of epilepsy. Journal of Clinical Psychiatry1997;58(1):3-11. [DOI: 10.4088/JCP.v58n0101]">Blumer 1997</a>). </p> <p>A further three studies were excluded because they did not report any primary or secondary outcome data and trial authors could not be contacted (<a href="./references#CD010682-bbs2-0012" title="HarmantJ , Van Rijckevorsel-HarmantK , De BarsyT , HendrickxB . Fluvoxamine: an antidepressant with low (or no) epileptogenic effect. Lancet1990;336(8711):386. ">Harmant 1990</a>; <a href="./references#CD010682-bbs2-0013" title="MachadoR , EspinosaA , MontotoA . Cholesterol concentrations and clinical response to sertraline in patients with epilepsy: preliminary results. Epilepsy &amp; Behavior2010;19:509-12. ">Machado 2010</a>; <a href="./references#CD010682-bbs2-0014" title="NCT00595699. Escitalopram treatment of major depression in patients with temporal lobe epilepsy. clinicaltrials.gov/ct/show/NCT00595699 (first posted 16 January 2008). ">NCT00595699</a>). </p> <p>See <a href="./references#CD010682-sec-0112" title="">Characteristics of excluded studies</a> for more details of the studies. </p> </section> </section> <section id="CD010682-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>We rated risk of bias across each domain for each study, and then made an overall judgement on risk of bias for each study, using the Cochrane 'Risk of bias' tool for the RCTs, and the ROBINS‐I tool for the NRSIs. </p> <p>See <a href="./references#CD010682-sec-0111" title="">Characteristics of included studies</a> for review authors' judgements about each 'Risk of bias' item for each included RCT, and <a href="#CD010682-tbl-0008">Table 2</a> for review authors' judgements about each 'Risk of bias' item for each included non‐randomised study. </p> <div class="table" id="CD010682-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias judgements for non‐randomised studies (ROBINS‐I)</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Domain and risk of bias judgement</b>  </p> </th> <th align="left" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b><a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b><a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias due to confounding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias in selection of participants into the study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias in classification of interventions</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias due to deviations from intended interventions</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias due to missing data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias in measurement of outcomes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias in selection of the reported result</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall judgement</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Support for judgement</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adjustment for confounding; unclear if participants were recruited consecutively; and by design, blinding was not possible, which may have influenced subjectively‐assessed outcomes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some analyses to investigate prognostic variables, but not a complete analysis of confounders; unclear which variables were of interest in advance, and if other characteristics were tested and analysed; and by design, blinding was not possible, which may have influenced subjectively‐assessed outcomes. The measure of depression was not an accurate or reliable measure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adjustment for confounding; many discontinuations due to adverse events and non‐compliance, with outcome data analysed by last observation carried forward; unclear if participants were already receiving the intervention on entry into the study, and exactly how groups were assigned. Lack of blinding may have influenced some participant‐reported outcomes. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some analyses to investigate prognostic variables, but not a complete analysis of confounders; unclear which variables were of interest in advance, and if other characteristics were tested and analysed; small groups and dropouts, with outcome data analysed by last observation carried forward, Lack of blinding may have influenced some participant‐reported outcomes. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adjustment for confounding; outcome data included only for those who completed analysis (6 participants excluded); and by design, blinding was not possible, which may have influenced subjectively‐assessed outcomes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adjustment for confounding; unclear if participants were recruited consecutively; and by design, blinding was not possible, which may have influenced subjectively‐assessed outcomes. </p> </td> </tr> </tbody> </table> </div> <p>Overall, we rated one RCT at low risk of bias (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>), three RCTs at unclear risk of bias (<a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>; <a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a>; <a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a>), and all six NRSIs at serious risk of bias. </p> <section id="CD010682-sec-0052"> <h4 class="title">Allocation</h4> <section id="CD010682-sec-0053"> <h5 class="title">Generation of random sequence and allocation concealment (RCTs)</h5> <p>We rated three RCTs at low risk of bias for sequence generation, as they used adequate methods (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>; <a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>; <a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a>). For allocation concealment, we rated <a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a> at unclear risk of bias, <a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a> at low risk of bias, and <a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a> at low risk of bias, as it was not possible to conceal allocation due to different treatment types (CBT versus sertraline). We rated the fourth RCT at unclear risk of bias for both sequence generation and allocation concealment (<a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a>). (See the '<a href="./references#CD010682-sec-0111" title="">Characteristics of included studies</a>' for more detailed information on methodology). </p> </section> <section id="CD010682-sec-0054"> <h5 class="title">Selection of participants into the study (NRSIs)</h5> <p>We judged two studies, which recruited consecutive participants over a specified time frame, to be at low risk of bias in the selection of participants into the study (<a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>); three studies to be at moderate risk of bias, as we were unclear if participants were consecutive, the time frame of recruitment was unclear, or we were unclear if participants were already taking an antidepressant at recruitment (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>; <a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a>); and one study to be at serious risk of bias, as although consecutive participants were recruited, only those who completed the intervention were included in the study results (<a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>). </p> </section> <section id="CD010682-sec-0055"> <h5 class="title">Classification of interventions (NRSIs)</h5> <p>We judged five studies to be at low risk of bias in classification of interventions: four studies had a before‐after design, measuring outcomes before and after treatment with antidepressant medications (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>, <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>; <a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a>), and one study allocated participants to antidepressants or CBT according to the feasibility of participants travelling to attend CBT (<a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>). We judged one study, with three treatment groups receiving different antidepressant medications, to be at moderate risk of bias, as it was unclear exactly how participants were assigned to these groups, and if they were already taking the treatment at recruitment into the study (<a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>). </p> </section> <section id="CD010682-sec-0056"> <h5 class="title">Deviations from intended interventions (NSRIs)</h5> <p>All studies aimed to assess the effect of starting and adhering to an intervention, and in all studies, all included participants received an intervention plus any anti‐seizure medications needed to maintain stability during the study. We judged three studies to be at low risk of bias, as all participants were included in the study and analysis (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>; <a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a>), and three studies to be at moderate risk of bias, since participants who discontinued the intervention or the study were not included in analysis (<a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>; <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>). </p> </section> </section> <section id="CD010682-sec-0057"> <h4 class="title">Blinding</h4> <section id="CD010682-sec-0058"> <h5 class="title">Blinding of participants, personnel, and outcome assessors (RCTs)</h5> <p>We rated two RCTs at low risk of bias, as study personnel, participants, and outcome assessors were blinded (<a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>; <a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a>). One RCT did not report any clear methods of blinding, therefore, we rated this study at unclear risk of bias (<a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a>). One RCT reported an absence of blinding for study personnel or participants due to different treatment interventions (CBT versus sertraline), but did report blinding of study investigators. Therefore, we rated this RCT at low risk of bias (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>). </p> </section> <section id="CD010682-sec-0059"> <h5 class="title">Measurement of outcomes (NSRIs)</h5> <p>By design, participants were not blinded in any of the six NRSIs, since they completed their own seizure diaries, in an un‐blinded manner. In one study, with three treatment groups receiving different antidepressant medications, a blinded outcome assessor assessed depression; in the other studies, depression was measured before and after the intervention in an un‐blinded manner. As lack of blinding may have influenced some participant‐reported or subjectively assessed outcomes, we judged five studies to be at moderate risk of bias due to measurement of outcomes (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>; <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>; <a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a>). We judged one study to be at serious risk of bias, because they used an insufficient measure of depression, by looking for 'complete resolution of identified target psychiatric symptoms' as a measure of response to treatment (<a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>). </p> </section> </section> <section id="CD010682-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>For the RCTs, two reported missing data and did not perform an intention‐to‐treat analysis, but they did report both numerator and denominator data (<a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>; <a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a>). We rated these as unclear risk of bias. The third RCT did not report any missing data and carried out an intention‐to‐treat analysis, therefore, we rated this study at low risk of bias (<a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a>). The fourth RCT reported missing data, with 15 participants lost to follow‐up, but reported an intention‐to‐treat analysis. We rated this study at low risk of bias (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>). </p> <p>We judged three NRSIs to be at low risk of bias, as they included all participants in the study; none of the participants discontinued the study (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a>), or all participants were included in an intention‐to‐treat analysis (<a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>). We judged three studies to be at serious risk of bias, since participants who discontinued the intervention or the study were not included in the analysis, or data were imputed using the simple method 'last observation carried forward', which assumes no change in outcomes, so this may have introduced bias into the results (<a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>; <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>). </p> </section> <section id="CD010682-sec-0061"> <h4 class="title">Selective reporting</h4> <p>We rated the four RCTs at low risk of bias, as they reported outcomes that were clearly stated in their methods section (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>; <a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>; <a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a>; <a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a>). </p> <p>We judged four NSRIs to be at low risk of bias in their selection of the reported results when summary statistics were presented for all outcomes defined in the methods, and no formal statistical analyses were conducted (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a>), or all outcomes and analyses defined in the methods were reported in the results (<a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>; <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>). We judged two studies to be at moderate risk of bias, when some participant characteristics were considered in the analyses, but the methods contained no details about which participant characteristics were of interest, and how many characteristics were examined and tested (<a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>).  </p> </section> <section id="CD010682-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <p>For one RCT, seizure data at baseline was collected retrospectively, so we judged this trial to be at high risk of recall bias (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>).  For the other RCTs, it was unclear whether there were any other potential sources of bias, so we rated all the RCTs as unclear risk of bias for this domain.  </p> <section id="CD010682-sec-0063"> <h5 class="title">Confounding variables (NSRIs)</h5> <p>We judged four studies to be at serious risk of bias due to confounding, as they conducted no adjustments for any confounding variables (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>; <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>; <a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a>); and we judged two studies to be at moderate risk of bias due to confounding, as they conducted some analyses to investigate differences in participant subgroups, but they did not consider all the important, prespecified confounders for this review, and it was unclear if the analyses were conducted specifically to investigate confounding (<a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>; see <a href="#CD010682-sec-0032">Assessment of risk of bias in included studies</a>).  </p> </section> </section> </section> <section id="CD010682-sec-0064"> <h3 class="title" id="CD010682-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD010682-tbl-0001"><b>Summary of findings 1</b> Paroxetine compared to doxepin for people with epilepsy and depression</a>; <a href="./full#CD010682-tbl-0002"><b>Summary of findings 2</b> Amitriptyline compared to nomifensine for people with epilepsy and depression</a>; <a href="./full#CD010682-tbl-0003"><b>Summary of findings 3</b> Venlafaxine compared to no treatment for people with epilepsy and depression</a>; <a href="./full#CD010682-tbl-0004"><b>Summary of findings 4</b> Sertraline compared to cognitive behavioural therapy for people with epilepsy and depression</a>; <a href="./full#CD010682-tbl-0005"><b>Summary of findings 5</b> Citalopram (before and after treatment) for people with epilepsy and depression</a>; <a href="./full#CD010682-tbl-0006"><b>Summary of findings 6</b> Selective serotonin reuptake inhibitors compared to cognitive behavioural therapy for people with epilepsy and depression</a> </p> <p>We evaluated six comparisons in this review:</p> <p> <ol id="CD010682-list-0025"> <li> <p>Paroxetine compared to doxepin for people with epilepsy and depression (<a href="./full#CD010682-tbl-0001">summary of findings Table 1</a>). We judged the certainty of evidence for this comparison to be moderate; evidence was downgraded due to imprecision, as only one small RCT contributed data. </p> </li> <li> <p>Amitriptyline compared to nomifensine for people with epilepsy and depression (<a href="./full#CD010682-tbl-0002">summary of findings Table 2</a>). We judged the certainty of evidence for this comparison to be low; we downgraded the evidence due to serious imprecision, as only one very small RCT contributed data. </p> </li> <li> <p>Venlafaxine compared to no treatment for people with epilepsy and depression (<a href="./full#CD010682-tbl-0003">summary of findings Table 3</a>). We judged the certainty of evidence for this comparison to be low; we downgraded the evidence due to risk of bias and imprecision, as only one small RCT contributed data. </p> </li> <li> <p>Sertraline compared to cognitive behavioural therapy (CBT) for people with epilepsy and depression (<a href="./full#CD010682-tbl-0004">summary of findings Table 4</a>). We judged the certainty of evidence for this comparison to be moderate to low; we downgraded the evidence due to risk of bias (lack of blinding, and retrospective collection of seizure frequency data at baseline). </p> </li> <li> <p>Citalopram (before and after) for people with epilepsy and depression (<a href="./full#CD010682-tbl-0005">summary of findings Table 5</a>). We judged the certainty of evidence for this comparison to be low to very low; we downgraded the evidence from two NRSIs due to serious risk of bias, and substantial statistical heterogeneity was present where data could be pooled. </p> </li> <li> <p>SSRIs (sertraline or citalopram) compared to cognitive behavioural therapy (CBT) for people with epilepsy and depression (<a href="./full#CD010682-tbl-0006">summary of findings Table 6</a>). We judged the certainty of evidence for this comparison to be very low; we downgraded the evidence due to serious risk of bias and imprecision, as only one very small NRSI of 15 participants contributed evidence, without any adjustment for confounding variables </p> </li> </ol> </p> <section id="CD010682-sec-0065"> <h4 class="title">Primary outcomes</h4> <section id="CD010682-sec-0066"> <h5 class="title">Depression scores</h5> <section id="CD010682-sec-0067"> <h6 class="title">1. Proportion with a greater than 50% improvement</h6> <p>Three of four RCTs reported on the proportion with a 50% or more improvement in depression scores. The RCTs analysed different treatment comparisons, and we were unable to combine the data in meta‐analysis. </p> <p><a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a> (N = 67) compared paroxetine (20 mg/day to 40 mg/day) to doxepin (mean dose 100 mg/day). There were 27/33 (82%) responders in the paroxetine group and 24/34 (71%) in the doxepin group. The risk ratio (RR) for the proportion with a 50% of more improvement in depression scores for paroxetine versus doxepin was 1.16 (95% confidence interval (CI) 0.88 to 1.52; P &gt; 0.05; <a href="./references#CD010682-fig-0002" title="">Analysis 1.1</a>). </p> <p><a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a> (N = 42) compared amitriptyline (75 mg/day), nomifensine (75 mg/day), and placebo. At 12 weeks, there were 6/14 (43%) responders in the amitriptyline group and 11/14 (79%) in the nomifensine group. The risk ratio for the proportion with a 50% or more improvement in depression scores for amitriptyline versus nomifensine was 0.55 (95% CI 0.28 to 1.06; P &gt; 0.05; <a href="./references#CD010682-fig-0006" title="">Analysis 2.1</a>). </p> <p><a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a> (N = 64) compared venlafaxine (25 mg/day to 75 mg/day) to no treatment. There were 22/32 (69%) responders in the venlafaxine group and 6/32 (19%) in the no treatment group. More participants had a 50% or more improvement in depression scores in the venlafaxine group than in the no treatment group (RR 3.25, 95% CI 1.19 to 8.90; P &lt; 0.05; <a href="./references#CD010682-fig-0007" title="">Analysis 3.1</a>). </p> <p>Four of the six NRSIs reported on the proportion of participants with a 50% or more improvement in depression scores. One study did not use a validated depression scale (<a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>). </p> <p><a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a> observed 28/43 (65%) participants with a 50% or more improvement in depression scores following eight weeks of treatment with citalopram (mean dose 23 mg/day) compared to baseline. </p> <p><a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a> observed 17/27 participants (52%) in the mirtazepine group (mean dose 32 mg/day), 12/33 participants (36%) in the citalopram group (mean dose 24 mg/day), and 8/15 participants (53%) in the reboxetine group (mean dose 7 mg/day) with a 50% or more improvement in depression scores following 20 to 30 weeks of treatment, compared to baseline.  </p> <p><a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a> observed 11/45 participants (24%) with a 50% or more improvement in depression scores following four months of treatment with citalopram (20 mg/day), compared to baseline. </p> <p><a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a> observed 35/36 participants (97%) with a 50% or more improvement in depression scores following one year of treatment with sertraline (mean dose 111 mg/day), or fluoxetine (mean 46 mg/day), compared to baseline. </p> </section> <section id="CD010682-sec-0068"> <h6 class="title">2. Mean difference</h6> <p>Three of the four RCTS reported on the mean difference in depression scores. Two RCTs used the HAMD scale (<a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>; <a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a>), and one used the BDI‐II (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>). The RCTs compared different treatment groups, and we were unable to combine the data in any meta‐analysis. </p> <p><a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a> (N = 140) compared sertraline (50 mg/day to 200 mg/day) to cognitive behavioural therapy (CBT). The mean difference (MD) in depression scores for sertraline versus CBT was ‐2.50 (95% CI ‐6.28 to 1.28) at 8 weeks, and ‐0.50 (95% CI ‐4.47 to 3.47) at 16 weeks (<a href="./references#CD010682-fig-0009" title="">Analysis 4.1</a>).  </p> <p><a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a> (N = 67) compared paroxetine (20 mg/day to 40 mg/day) and doxepin (mean dose 100 mg/day). The mean difference in depression scores following treatment for paroxetine versus doxepin was 0.65 (95% CI ‐2.15 to 3.45; <a href="./references#CD010682-fig-0003" title="">Analysis 1.2</a>).  </p> <p><a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a> (N = 64) compared venlafaxine (25 mg to 75 mg/day) versus no treatment. Depression scores following treatment with venlafaxine were better than in the no treatment group (MD ‐7.59, 95% CI ‐11.52 to ‐3.66; <a href="./references#CD010682-fig-0008" title="">Analysis 3.2</a>).  </p> <p>Four out of the six NSRIs reported on the mean difference in depression scores; either the mean difference before and after citalopram treatment (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>), or the mean difference between treatment groups following treatment (<a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>). </p> <p>We were able to meta‐analyse data from two before‐after studies of citalopram. The average dose of citalopram was 22 mg/day in <a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>, and 20 mg/day in <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>. The standardised mean difference (SMD) in depression scores indicated a large effect, with an estimate of 1.17 (95% CI 0.96 to 1.38; 2 studies, 88 participants; <a href="./references#CD010682-fig-0017" title="">Analysis 5.1</a>). The I² was 53%, which may reflect differences between the treatment periods. <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a> reported outcomes following four months of treatment; <a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a> after two months of treatment. Due to the level of statistical heterogeneity, we conducted a random‐effects analysis, which showed similar results (SMD 1.17; 95% CI 0.86 to 1.47). </p> <p><a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a> reported mean depression scores before and after treatment with mirtazepine, citalopram, and reboxetine. From baseline to 20 to 30 weeks of treatment, the mean depression scores on the HAMD decreased with mirtazepine from 23 to 13.5, citalopram from 22.5 to 14, and reboxetine from 23 to 13.5.  </p> <p><a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a> reported mean depression scores before and after treatment with an SSRI (sertraline or citalopram) versus CBT. The mean difference in depression scores for SSRIs versus CBT was ‐2.60 (95% CI ‐11.58 to 6.38) following six weeks of treatment; and ‐4.90 (95% CI ‐14.60 to 4.80; <a href="./references#CD010682-fig-0019" title="">Analysis 6.1</a>) following 12 weeks of treatment.   </p> </section> <section id="CD010682-sec-0069"> <h6 class="title">3. Remission</h6> <p>One of the four RCTs reported the proportion of participants who achieved a remission in depressive symptoms. </p> <p><a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a> reported 38/72 (53%) participants in the sertraline group and 41/68 (60%) in the CBT group who achieved a remission in depressive symptoms, measured on the MINI at 16 weeks of treatment (RR 0.88, 95% CI 0.65 to 1.17; 140 participants; <a href="./references#CD010682-fig-0010" title="">Analysis 4.2</a>). </p> <p>One of the six NRSIs reported the proportion of participants who achieved a remission in depressive symptoms. </p> <p><a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a> observed 7/8 (87%) in the SSRI group and 4/7 (57%) in the CBT group who achieved a remission in depressive symptoms, measured on the BDI (BDI &lt; 14) at 12 weeks of treatment (RR 1.53, 95% CI 0.77 to 3.06; 15 participants; <a href="./references#CD010682-fig-0020" title="">Analysis 6.2</a>). </p> </section> </section> <section id="CD010682-sec-0070"> <h5 class="title">Seizure frequency</h5> <section id="CD010682-sec-0071"> <h6 class="title">1. Mean difference</h6> <p>One RCT reported mean difference in seizure frequency between baseline and end of treatment period (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>). One RCT reported no change in seizure frequency in either the paroxetine or the doxepin treatment groups (<a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>). </p> <p><a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a> reported inconclusive results for a change in the average number of generalised tonic‐clonic seizure (GTCS) per month at eight weeks (MD ‐0.10, 95% CI ‐0.26 to 0.06), and 16 weeks (MD 0.00, 95% CI ‐0.10 to 0.10) of treatment with either sertraline or CBT; and for focal seizures with impaired awareness at eight weeks (MD ‐2.60, 95% CI ‐6.52 to 1.32), and 16 weeks (MD ‐3.00, 95% CI ‐7.81 to 1.81; <a href="./references#CD010682-fig-0011" title="">Analysis 4.3</a>) of treatment with either sertraline or CBT. </p> <p>Four of the six NRSIs reported on changes in mean seizure frequency; either the mean difference before and after citalopram treatment (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>), or the mean difference between treatment groups following treatment (<a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>). </p> <p>We conducted a meta‐analysis with data from the two before‐after studies of citalopram (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>). Calculating SMD, and using both a fixed‐effect and random‐effects model, the I² was 81%. Therefore, we did not report the pooled effect estimate. Individually, <a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a> showed inconclusive results between groups (MD 0.03, 95% CI ‐0.23 to 0.30; 43 participants), while <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a> showed possible improvement after treatment (MD 0.50, 95% CI 0.21 to 0.78; 45 participants; <a href="./references#CD010682-fig-0018" title="">Analysis 5.2</a>). Possible reasons for a high I² value are differences in mean baseline seizure frequency, treatment duration, and mean age of participants. </p> <p><a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a> reported no statistically significant difference in seizure frequency between baseline and post‐treatment for the 100 participants treated with sertraline (mean dose 108 mg/day). </p> <p>The results for a change in seizure frequency between baseline and 12 weeks of treatment, between the eight participants receiving an SSRI (sertraline or citalopram) and the seven participants receiving CBT, were inconclusive (MD ‐1.60, 95% CI ‐5.63 to 2.43; 15 participants; <a href="./references#CD010682-fig-0021" title="">Analysis 6.3</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>). </p> </section> <section id="CD010682-sec-0072"> <h6 class="title">2. Seizure recurrence</h6> <p>One RCT reported on the recurrent of GTCS during the study in participants who had not experienced a GTCS in the six months prior to enrolment (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>). It reported a recurrence in 4/51 people in the sertraline group versus 4/53 in the CBT (RR 1.04, 95% CI 0.27 to 3.94; 104 participants; <a href="./references#CD010682-fig-0012" title="">Analysis 4.4</a>). </p> <p>One NRSI reported that one participant experienced a recurrence of seizures (<a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>). </p> </section> <section id="CD010682-sec-0073"> <h6 class="title">3. Episode of status epilepticus</h6> <p>None of the 10 studies reported episodes of status epilepticus.</p> </section> </section> </section> <section id="CD010682-sec-0074"> <h4 class="title">Secondary outcomes</h4> <section id="CD010682-sec-0075"> <h5 class="title">Withdrawals for any reason</h5> <p>Three of the RCTs clearly reported the number of participants who withdrew for any reason (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>; <a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>; <a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a>). </p> <p><a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a> reported 7/72 withdrawals in the sertraline group (three withdrew consent; four left the study due to worsening depression), and 6/68 in the CBT group (two withdrew consent; four left the study due to worsening depression). There were also 9/72 participants lost to follow‐up from the sertraline group, and 6/68 from the CBT group (RR 1.26, 95% CI 0.64 to 2.46; 140 participants; <a href="./references#CD010682-fig-0013" title="">Analysis 4.5</a>). </p> <p><a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a> reported that 3/34 participants (9%) withdrew from the doxepin group versus 0/33 from the paroxetine group (RR 0.15, 95% CI 0.01 to 2.74; P = 0.20; 67 participants; <a href="./references#CD010682-fig-0004" title="">Analysis 1.3</a>). The specific reasons for withdrawal were not reported.  </p> <p><a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a> reported that 1/14 participants (7%) withdrew from the amitriptyline group, 1/14 from the nomifensine group, and 1/14 from the placebo group. The participant withdrew from the nomifensine group because of increased seizures; the other reasons were not reported. </p> <p>All six prospective non‐randomised studies reported on the number of participants withdrawing from the study. </p> <p><a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a> reported no treatment withdrawals from the study. </p> <p><a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a> reported that 18/100 participants (18%) withdrew due to adverse events from the sertraline. </p> <p><a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a> reported that 20/27 participants (74%) withdrew from the mirtazepine group, 16/33 participants (48%) from the citalopram group, and 6/15 participants (40%) from the reboxetine group withdrew after 20 to 30 weeks of treatment. Adverse events accounted for 8/20 withdrawals from the mirtazepine group, 6/16 from the citalopram group, and 3/6 from the reboxetine group. Three participants (two from mirtazepine and one from citalopram) withdrew due to inefficacy. The remaining 22 participants were lost to follow‐up. </p> <p><a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a> reported that 2/7 withdrew from the CBT group (1 due to health problems unrelated to epilepsy, and 1 due to severe psychosocial situation deemed unrelated to either epilepsy or depression). There were no withdrawals from the SSRI group, but one was lost to follow‐up due to a road traffic accident. There were inconclusive results between groups (RR 0.44, 95% CI 0.05 to 3.85; 15 participants; <a href="./references#CD010682-fig-0022" title="">Analysis 6.4</a>). </p> <p><a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a> reported that 6/45 participants (13%) withdrew from the study (four because of adverse events from the citalopram, one due to poor compliance, and one due to concurrent illness). </p> <p><a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a> reported that 1/36 participant, treated with sertraline (SSRI) withdrew because of an exacerbation of seizures. </p> </section> <section id="CD010682-sec-0076"> <h5 class="title">Global State</h5> <p>None of the included studies reported on global state outcomes.</p> </section> <section id="CD010682-sec-0077"> <h5 class="title">Mental State</h5> <p>None of the included studies reported on mental state outcomes.</p> </section> <section id="CD010682-sec-0078"> <h5 class="title">General Functioning</h5> <p>None of the included studies reported on general functioning outcomes.</p> </section> <section id="CD010682-sec-0079"> <h5 class="title">Cognitive Functioning</h5> <p>None of the included studies reported on cognitive functioning outcomes.</p> </section> <section id="CD010682-sec-0080"> <h5 class="title">Quality of life</h5> <p>One of the four RCTs assessed quality of life, using the 89‐item Quality of Life in Epilepsy Inventory (QOLIE‐89; (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>)). </p> <p>There were inconclusive results in improved quality of life between the sertraline and CBT groups at 8 weeks (MD 6.10, 95% CI ‐0.28 to 12.48; 104 participants), and at 16 weeks (MD 3.10, 95% CI ‐3.41 to 9.61; 118 participants <a href="./references#CD010682-fig-0014" title="">Analysis 4.6</a>).  </p> <p>One of the six NRSIs assessed quality of life with the QOLIE‐31 (<a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>).  </p> <p>There were inconclusive results between groups (MD ‐0.50, 95% CI ‐19.67 to 18.67; 15 participants; <a href="./references#CD010682-fig-0023" title="">Analysis 6.5</a>) </p> </section> <section id="CD010682-sec-0081"> <h5 class="title">Behaviour</h5> <p>None of the included studies reported on behaviour outcomes.</p> </section> <section id="CD010682-sec-0082"> <h5 class="title">Adverse effects</h5> <p>Two RCTs reported the number of participants who experienced specific side effects (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>; <a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>). </p> <p><a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a> compared paroxetine and doxepin. </p> <p>The results were inconclusive between groups for blurred vision (RR 0.34, 99% CI 0.09 to 1.32; 67 participants), dizziness (RR 0.21, 99% CI 0.03 to 1.37; 67 participants), dry mouth (RR 0.26, 99% CI 0.06 to 1.20; 67 participants), sleep disorders (RR 0.32, 99% CI 0.08 to 1.20; 67 participants), and urinary retention (RR 0.34, 99% CI 0.01 to 21.99; 67 participants; <a href="./references#CD010682-fig-0005" title="">Analysis 1.4</a>).  </p> <p><a href="http://Gilliam 2019" target="_blank">Gilliam 2019</a> compared sertraline and CBT. </p> <p>There were 10 serious adverse events in the sertraline group, three of which were possibly related to the study (one mania and psychosis, two worsening depression requiring hospitalisation). There were 12 serious adverse events in the CBT group, three of which were possibly related to the study (worsening depression and suicidal). One participant in the CBT group died of sudden unexpected death in epilepsy (SUDEP). </p> <p>The difference in adverse events profile (AEP) scores was inconclusive between the groups at 8 weeks (MD ‐2.70, 95% CI ‐6.62 to 1.22; 106 participants), and 16 weeks (MD ‐2.10, 95% CI ‐6.21 to 2.01; 118 participants; <a href="./references#CD010682-fig-0015" title="">Analysis 4.7</a>).  </p> <p>There were more cases of tiredness reported by the participants on sertraline compared to those receiving CBT (RR 3.54, 99% CI 1.40 to 8.96; 140 participants; <a href="./references#CD010682-fig-0016" title="">Analysis 4.8</a>) </p> <p>Results were inconclusive between the groups for the other five most commonly reported adverse events: headache (RR 1.48, 99% CI 0.69 to 3.19), insomnia (RR 2.16, 99% CI 0.73 to 6.38), shakiness (RR 12.28, 99% CI 0.88 to 171.59), nausea (RR 2.60, 99% CI 0.62 to 10.96), and diarrhoea (RR 19.85, 99% CI 0.49 to 805.53; 140 participants; <a href="./references#CD010682-fig-0016" title="">Analysis 4.8</a>).  </p> <p>Five of six NRSIs reported on adverse events. The studies analysed different treatment comparisons, so we were unable to combine the data in meta‐analysis. </p> <p><a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a> reported that 3/43 participants (7%) experienced nausea, and 2/43 (5%) experienced sexual dysfunction following eight weeks of treatment with citalopram. </p> <p><a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a> reported that 9/100 participants (9%) experienced sedation, 7/100 (7%) experienced hypomanic symptoms, 1/100 (1%) experienced rheumatic pain, and 1/100 participants (1%) experienced myoclonus following an average of 10 months on sertraline. </p> <p><a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a> reported that 13/75 participants experienced side effects. The most common were; weight gain (5/75), sedation (2/75), and sexual dysfunction (2/75). </p> <p><a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a> reported that 22/45 participants (56%) experienced side effects. The most common were; headache (15%), nausea (11%), dizziness (9%), drowsiness (7%), and fatigue (7%). </p> <p><a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a> reported that 1/36 participants (3%) experienced facial rash, and 1/36 (3%) experienced gastrointestinal disorders. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010682-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010682-sec-0083"></div> <section id="CD010682-sec-0084"> <h3 class="title" id="CD010682-sec-0084">Summary of main results</h3> <p>We identified four randomised controlled trials (RCTs; N = 313) of antidepressant treatment for people with epilepsy, three of which had small sample sizes (42 to 67 participants). One trial compared antidepressant medication with cognitive behavioural therapy (CBT). Venlafaxine improved depressive symptoms when compared to no treatment; amitriptyline was not better than nomifensine in improving depressive symptoms; depressive symptoms were improved with both sertraline or CBT, but one was not better than the other. The RCTs did not allow meaningful comparisons among the different classes of antidepressants. Therefore, we do not know which antidepressant or class of antidepressant is most effective. </p> <p>Only one RCT reported on changes in seizure frequency. The results were inconclusive for a change in frequency of generalised tonic clonic seizures for sertraline or CBT. Only one RCT reported on adverse events. The results were inconclusive between groups for adverse events including suicidal risk except tiredness which occurred more often in the sertraline group. The top reported side effects were; sedation, headache, insomnia and gastrointestinal symptoms. </p> <p>The six prospective cohort studies (N = 313) were of serious risk of bias examining small numbers of participants treated predominantly with selective serotonin reuptake inhibitors (SSRIs). One study compared SSRIs to CBT. The combined meta‐analysis of two studies examining citalopram at 20 mg/day showed that citalopram improved depressive symptoms.  We could not combine the data on changes in seizure frequency due to marked heterogeneity. However, in the three studies reporting changes in seizure frequency, the results were inconclusive. Only one study reported on one participant on antidepressant treatment (citalopram) who experienced seizure recurrence. Whilst the data are of low certainty in terms of impact on seizures, there is broad agreement across the prospective cohort studies of limited or no impact on seizures with selective serotonin reuptake inhibitors (SSRIs). </p> <p>Participants withdrawing from antidepressants were more likely to do so because of adverse events rather than lack of efficacy. Reported adverse events for SSRIs included nausea, dizziness, sedation, gastrointestinal disturbance, and sexual dysfunction. We have no reliable information on the comparative risk of adverse events with different classes of antidepressant treatment. </p> </section> <section id="CD010682-sec-0085"> <h3 class="title" id="CD010682-sec-0085">Overall completeness and applicability of evidence</h3> <p>This review has ascertained that there is very limited evidence of an effect of antidepressants on depressive symptoms in participants with epilepsy. Depressive symptoms were improved with both sertraline or CBT, but one was not better than the other. We do not have any reliable high certainty evidence to inform on the best choice of antidepressant drug or class of drug for treating depression with the lowest risk of seizure exacerbation. </p> </section> <section id="CD010682-sec-0086"> <h3 class="title" id="CD010682-sec-0086">Quality of the evidence</h3> <p>Overall, we rated one study at low risk of bias (<a href="./references#CD010682-bbs2-0001" title="GilliamFG , BlackKJ , CarterJ , FreedlandKE , ShelineYI , Tsai W-Y, et al. A trial of sertraline or cognitive behavior therapy for depression in epilepsy. Annals of Neurology2019;86(4):552-60. [DOI: https://dx.doi.org/10.1002/ana.25561] [ISSN: 1531-8249] [PMID: 31359460]">Gilliam 2019</a>), five prospective cohort studies at high risk of bias (<a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a>; <a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a>; <a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>; <a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>; <a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a>) and four studies (three RCTs and one prospective cohort study) at unclear risk of bias (<a href="./references#CD010682-bbs2-0005" title="LiW , MaD . A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation2005;9(12):20-1. ">Li 2005</a>; <a href="./references#CD010682-bbs2-0007" title="RobertsonM , TrimbleM . The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders1985;9:127-36. ">Robertson 1985</a>; <a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>; <a href="./references#CD010682-bbs2-0010" title="ZhuS , LuoL , GuiY . Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation2004;19(2):101. ">Zhu 2004</a>). </p> <p>The 'Summary of findings' tables for each comparison examined shows that the certainty of the evidence for the outcomes ranged from moderate certainty to low certainty. For comparisons where RCTs were available, we downgraded for imprecision as for these comparisons, only one small study contributed to the outcomes. For comparisons where only NRSIs were available, we rated the certainty of evidence as low to very low and evidence was downgraded due to risk of bias, imprecision and substantial heterogeneity for some outcomes. </p> </section> <section id="CD010682-sec-0087"> <h3 class="title" id="CD010682-sec-0087">Potential biases in the review process</h3> <p>It is possible that despite the exhaustive searches carried out in this review, we did not identify other sources of unpublished data. This can be more of an issue for reviews including non‐randomised study designs, such as this review. </p> <p>Including non‐randomised evidence, which is inherently at risk of additional biases to RCT evidences, may have also introduced bias into the review. However, as stated in <a href="#CD010682-sec-0017">Types of studies</a>, prospective non‐randomised studies may be more reflective of clinical practice in terms of the populations recruited, and because of the known delayed effect of antidepressants on depressive symptoms, which may not be effectively detected in short‐term randomised trials.  </p> <p>We carried out a detailed quality assessment of the non‐randomised studies included in this review, using an appropriate tool (ROBINS‐I), and interpreted evidence from the non‐randomised studies taking into account the likely biases present within these studies. </p> </section> <section id="CD010682-sec-0088"> <h3 class="title" id="CD010682-sec-0088">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of any other reviews on this topic.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010682-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD010682-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: RCT: paroxetine versus doxepin, Outcome 1: &gt; 50% reduction in depressive symptoms" data-id="CD010682-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: RCT: paroxetine versus doxepin, Outcome 1: &gt; 50% reduction in depressive symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: RCT: paroxetine versus doxepin, Outcome 2: Mean depression scores" data-id="CD010682-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: RCT: paroxetine versus doxepin, Outcome 2: Mean depression scores</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: RCT: paroxetine versus doxepin, Outcome 3: Withdrawals (any reason)" data-id="CD010682-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: RCT: paroxetine versus doxepin, Outcome 3: Withdrawals (any reason)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: RCT: paroxetine versus doxepin, Outcome 4: Adverse effects" data-id="CD010682-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: RCT: paroxetine versus doxepin, Outcome 4: Adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RCT: amitriptyline versus nomifensine, Outcome 1: &gt; 50% reduction in depressive symptoms" data-id="CD010682-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: RCT: amitriptyline versus nomifensine, Outcome 1: &gt; 50% reduction in depressive symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: RCT: venlafaxine versus no treatment controls, Outcome 1: &gt; 50% reduction in depressive symptoms" data-id="CD010682-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: RCT: venlafaxine versus no treatment controls, Outcome 1: &gt; 50% reduction in depressive symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: RCT: venlafaxine versus no treatment controls, Outcome 2: Mean depression scores ‐ HAMD" data-id="CD010682-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: RCT: venlafaxine versus no treatment controls, Outcome 2: Mean depression scores ‐ HAMD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 1: Mean depression scores (BDI)" data-id="CD010682-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 1: Mean depression scores (BDI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 2: Remission in depressive symptoms" data-id="CD010682-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 2: Remission in depressive symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 3: Seizure frequency" data-id="CD010682-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 3: Seizure frequency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 4: Seizure recurrence" data-id="CD010682-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 4: Seizure recurrence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 5: Withdrawals (any reason)" data-id="CD010682-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 5: Withdrawals (any reason) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 6: Quality of life (QOLIE‐89)" data-id="CD010682-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 6: Quality of life (QOLIE‐89) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 7: Adverse events profile" data-id="CD010682-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 7: Adverse events profile </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 8: Adverse events" data-id="CD010682-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: RCT: sertraline versus cognitive behavioural therapy (CBT), Outcome 8: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: NRSI: citalopram (before and after), Outcome 1: Mean depression scores HAMD‐21" data-id="CD010682-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: NRSI: citalopram (before and after), Outcome 1: Mean depression scores HAMD‐21 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: NRSI: citalopram (before and after), Outcome 2: Mean monthly seizure frequency" data-id="CD010682-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: NRSI: citalopram (before and after), Outcome 2: Mean monthly seizure frequency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: NRSI: SSRIs (sertraline or citalopram) versus CBT, Outcome 1: Mean depression scores (BDI)" data-id="CD010682-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: NRSI: SSRIs (sertraline or citalopram) versus CBT, Outcome 1: Mean depression scores (BDI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: NRSI: SSRIs (sertraline or citalopram) versus CBT, Outcome 2: Remission in depressive symptoms" data-id="CD010682-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: NRSI: SSRIs (sertraline or citalopram) versus CBT, Outcome 2: Remission in depressive symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: NRSI: SSRIs (sertraline or citalopram) versus CBT, Outcome 3: Seizure frequency per month at 12 weeks" data-id="CD010682-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: NRSI: SSRIs (sertraline or citalopram) versus CBT, Outcome 3: Seizure frequency per month at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: NRSI: SSRIs (sertraline or citalopram) versus CBT, Outcome 4: Withdrawals (any reason)" data-id="CD010682-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: NRSI: SSRIs (sertraline or citalopram) versus CBT, Outcome 4: Withdrawals (any reason) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010682-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/urn:x-wiley:14651858:media:CD010682:CD010682-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: NRSI: SSRIs (sertraline or citalopram) versus CBT, Outcome 5: Quality of life (QOLIE‐31 overall score)" data-id="CD010682-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_t/tCD010682-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: NRSI: SSRIs (sertraline or citalopram) versus CBT, Outcome 5: Quality of life (QOLIE‐31 overall score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/media/CDSR/CD010682/image_n/nCD010682-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010682-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Paroxetine compared to doxepin for people with epilepsy and depression</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Paroxetine compared to doxepin for people with epilepsy and depression</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with epilepsy and depression<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> paroxetine<br/><b>Comparison:</b> doxepin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>doxepin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>paroxetine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&gt; 50% reduction in depressive symptoms</b> </p> <p><i>Follow‐up: 8 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>706 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>819 per 1000</b><br/>(621 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b> <br/>(0.88 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean depression scores</b> </p> <p>(HAMD scores; lower = better)</p> <p><i>Follow‐up: 8 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HAMD depression score in the intervention groups was<br/><b>0.65 higher</b><br/>(2.15 lower to 3.45 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizure frequency</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> </p> <p><i>Follow‐up: 8 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b><br/>(1 to 242) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.15</b> <br/>(0.01 to 2.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>doxepin: 3 withdrew</p> <p>paroxetine: 0 withdrew</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p><i>Follow‐up: 8 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Reported adverse events: blurred vision, dizziness, dry mouth, sleep disorders, and urinary retention </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Reported adverse events: blurred vision, dizziness, dry mouth, and sleep disorders</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no significant differences between treatment groups for any reported adverse events </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b>  is the event rate in the doxepin group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HAMD:</b> Hamilton Rating Scale for Depression; <b>NA</b> : not applicable;<b> RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty.</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty,</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty.</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty.</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Certainty of the evidence downgraded for imprecision, because only one small study contributed to the outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Paroxetine compared to doxepin for people with epilepsy and depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010682-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Amitriptyline compared to nomifensine for people with epilepsy and depression</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Amitriptyline compared to nomifensine for people with epilepsy and depression</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with epilepsy and depression<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> amitriptyline<br/><b>Comparison:</b> nomifensine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>nomifensine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>amitriptyline</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&gt; 50% reduction in depressive symptoms</b> </p> <p><i>Follow‐up: 12 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>786 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>432 per 1000</b><br/>(220 to 833) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.55</b> <br/>(0.28 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean depression scores</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure frequency</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is the event rate in the nomifensine group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>NA</b> : not applicable;<b> RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty.</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty,</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty.</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty.</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Certainty of the evidence downgraded twice for imprecision, because only very small study contributed limited outcome data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Amitriptyline compared to nomifensine for people with epilepsy and depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010682-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Venlafaxine compared to no treatment for people with epilepsy and depression</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Venlafaxine compared to no treatment for people with epilepsy and depression</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with epilepsy and depression<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> venlafaxine<br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>venlafaxine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&gt; 50% reduction in depressive symptoms</b> </p> <p><i>Follow‐up: 8 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>406 per 1000</b><br/>(149 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.25</b> <br/>(1.19 to 8.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean depression scores</b> </p> <p>(HAMD scores; lower = better)</p> <p><i>Follow‐up: 8 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HAMD depression score in the intervention group was<br/><b>7.59 lower</b><br/>(11.52 lower to 3.66 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Seizure frequency</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawals</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/>(0 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognitive functioning</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b>  is the event rate in the no treatment group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HAMD:</b> Hamilton Rating Scale for Depression; <b>NA</b> : not applicable;<b> RCT</b> : randomised controlled trial;  <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty.</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty,</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty.</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty.</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Certainty of the evidence downgraded for imprecision, because only one small study contributed to the outcomes. <br/><sup>b</sup>Certainty of the evidence downgraded once due to risk of bias; unclear methodological information provided regarding randomisation and allocation concealment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Venlafaxine compared to no treatment for people with epilepsy and depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010682-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sertraline compared to cognitive behavioural therapy for people with epilepsy and depression</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Sertraline compared to cognitive behavioural therapy for people with epilepsy and depression</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with epilepsy and depression<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> sertraline<br/><b>Comparison:</b> cognitive behavioural therapy (CBT) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CBT</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>sertraline</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&gt; 50% reduction in depressive symptoms</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean depression scores</b> </p> <p>(BDI scores; lower = better)</p> <p><i>Follow‐up: 16 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BDI depression score in the intervention group was <b>0.50 lower</b> (4.47 lower to 3.47 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 8 weeks: MD ‐2.50 (95% CI ‐6.28 to 1.28; 104 participants)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure frequency</b> </p> <p><i>Follow‐up: 16 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of GTCS per month in the intervention group was <b>0 lower</b> (‐0.10 lower to 0.10 higher) </p> <p>The mean frequency of focal seizures with impaired awareness per month in the intervention group was <b>3.00 lower</b> (7.81 lower to 1.81 higher)   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 with GTCS plus 75 with focal seizures</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 8 weeks:</p> <p>GTCS per month: MD ‐0.10 (95% CI ‐0.26 to 0.06; 86 participants)</p> <p>focal seizures with impaired awareness per month: MD ‐2.60 (95% CI ‐6.52 to 1.32; 75 participants) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> </p> <p><i>Follow‐up: 16 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> <p>(113 to 434 per 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.26</b> (0.64 to 2.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBT: 6 withdrew, 6 lost to follow‐up</p> <p>sertraline: 7 withdrew, 9 lost to follow‐up</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>(QOLIE‐89 scale; lower = better)</p> <p><i>Follow‐up: 16 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean QOLIE‐89 score in the intervention group was <b>3.10 higher</b> (3.41 lower to 9.61 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>at 8 weeks: MD 6.10 (95% CI ‐0.28 to 12.48; 104 participants)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p><i>Follow‐up: 16 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean adverse event profile score in the intervention group was <b>2.10 lower </b>(6.21 lower to 2.01 higher)  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>low<sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sertraline resulted in more cases of tiredness than CBT (RR 3.54, 99% CI 1.40 to 8.96; 140 participants) </p> <p>Sertraline did not result in more cases of any other adverse effects than CBT.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is the event rate in the CBT group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BDI</b> : Beck Depression Inventory; <b>CBT</b> : cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>MD</b> : mean difference; <b>NA</b> : not applicable;<b> QOLIE:</b> Quality of life in Epilepsy<b>; RCT</b> : randomised controlled trial;  <b>RR:</b> risk ratio; <b>GTCS</b>: generalised tonic‐clonic seizures </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty.</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty,</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty.</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty.</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Certainty of the evidence downgraded once due to risk of bias: participants and personnel not blinded, and lack of blinding may have influenced outcome<br/><sup>b</sup>Certainty of the evidence downgraded twice due to risk of bias and imprecision: risk of recall bias as seizure frequency data at baseline was collected retrospectively, and data not available for all participants </p> <p><sup>c</sup>Certainty of the evidence downgraded once due to imprecision: adverse event data not available for all participants who received an intervention </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sertraline compared to cognitive behavioural therapy for people with epilepsy and depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010682-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Citalopram (before and after treatment) for people with epilepsy and depression</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>Citalopram (before and after treatment) for people with epilepsy and depression</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with epilepsy and depression<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> citalopram<br/><b>Control:</b> before citalopram treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Citalopram (before and after)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <b>&gt; 50% reduction in depressive symptoms</b> </p> <p><i>Follow‐up: 4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 out of 45 participants (24%) showed a 50% or more improvement in depression scores after treatment compared to baseline.<br/>  </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1 NRSI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean depression scores</b> </p> <p>(HAMD scores; lower = better)</p> <p><i>Follow‐up: 8 weeks to 4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Improved depression scores were shown after citalopram compared to before (see comment) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88<br/>(2 NRSI) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD in HAMD score was 1.17 (95% CI 0.96 to 1.38), indicating improved outcomes and a large treatment effect. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure frequency</b> </p> <p><i>Follow‐up: 8 weeks to 4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88<br/>(2 NRSI) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>very low<sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results were mixed between studies; due to very high heterogeneity (I² = 81%), we did not present the overall effect estimate. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> </p> <p><i>Follow‐up: 8 weeks to 4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6/45 participants (13%) withdrew from one study; 0/43 from the other study</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88</p> <p>(2 NRSI)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>low<sup>a</sup><br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p><i>Follow‐up: 8 weeks to 4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22/45 participants (56%) experienced adverse events in one study; 5/43 (12%) in the other study </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88</p> <p>(2 NRSI)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>low<sup>a</sup>   </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific adverse events reported: nausea, sexual dysfunction, headache, dizziness, drowsiness, and fatigue </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI:</b> confidence interval; <b>HAMD:</b> Hamilton Rating Scale for Depression; <b>NRSI</b>: non‐randomised studies of interventions </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty.</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty,</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty.</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty.</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Certainty of the evidence downgraded twice as studies were judged to be at serious risk of bias due to lack of blinding, which may have influenced participant‐recorded outcomes, and lack of adjustment for confounding variables. <br/><sup>b</sup>Certainty of the evidence upgraded once as large effect found.<br/><sup>c</sup>Certainty of the evidence downgraded due to inconsistency: substantial statistical heterogeneity was present (I² &gt; 50%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Citalopram (before and after treatment) for people with epilepsy and depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010682-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Selective serotonin reuptake inhibitors compared to cognitive behavioural therapy for people with epilepsy and depression</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p>Selective serotonin reuptake inhibitors<b>compared to cognitive behavioural therapy for people with epilepsy and depression</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> people with epilepsy and depression<br/><b>Settings:</b> outpatients<br/><b>Intervention:</b> selective serotonin reuptake inhibitors (SSRIs; sertraline or citalopram)<br/><b>Comparison:</b> cognitive behavioural therapy (CBT) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CBT</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SSRIs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>&gt; 50% reduction in depressive symptoms</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean depression scores</b> </p> <p>(BDI scores; lower = better)</p> <p><i>Follow‐up: 12 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BDI depression score in</p> <p>the intervention group was <b>4.90 lower </b>(14.90 lower to 4.80 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15<br/>(1 NRSI) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝ </p> <p>very low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>at 6 weeks: MD ‐2.60 (95% CI ‐11.58 to 6.38; 15 participants)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure frequency</b> </p> <p><i>Follow‐up: 12 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of seizures per month in the intervention group was <b>1.60 lower</b> (5.63 lower to 2.43 higher)  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (1 NRSI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> </p> <p><i>Follow‐up: 12 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> <p>(14 to 1000 per 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.44</b>  </p> <p>(0.05 to 3.85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (1 NRSI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>very low<sup>a</sup><sup>,b</sup>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBT: 2 lost to follow‐up</p> <p>SSRI: 1 lost to follow‐up in the</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive functioning</b> </p> <p><i>Follow‐up: NA</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life ‐ QOLIE‐31 scale</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean QOLIE‐31 score in the intervention group was <b>0.50 lower </b>(19.67 lower to 18.67 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (1 NRSI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>1,2</sup>  </p> <p><b>very</b>  <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects ‐ adverse event profile</b> </p> <p><i>Follow‐up: 16 weeks</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> is the event rate in the CBT group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>BDI</b> : Beck Depression Inventory; <b>CBT</b> : cognitive behavioural therapy; <b>CI:</b> confidence interval; <b>MD</b> : mean difference; <b>NA</b> : not applicable;<b> QOLIE:</b> Quality of life in Epilepsy<b>; RCT</b> : randomised controlled trial;  <b>RR:</b> risk ratio; <b>SSRI</b>: selective serotonin reuptake inhibitors </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty.</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty,</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty.</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty.</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Certainty of the evidence downgraded twice as the study was judged to be at serious risk of bias with regards to lack of blinding which may have influenced participant recorded outcomes and lack of adjustment for confounding variables.  </p> <p>2. Certainty of the evidence downgraded once due to imprecision: very small study of 15 participants, confidence intervals around effect estimates wide </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Selective serotonin reuptake inhibitors compared to cognitive behavioural therapy for people with epilepsy and depression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010682-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria for overall risk of bias judgements from ROBINS‐I</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk of bias judgement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Criteria based on seven risk of bias domains</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low risk of bias:</b> the study is comparable to a well‐performed randomised trial </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study is judged to be at low risk of bias for all domains</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate risk of bias:</b> the study appears to provide sound evidence for a non‐randomised study but cannot be considered comparable to a well‐performed randomised trial </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study is judged to be at low or moderate risk of bias for all domains</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious risk of bias:</b> the study has some important problems </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study is judged to be at serious risk of bias in at least 1 domain, but not at critical risk of bias in any domain </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Critical risk of bias:</b> the study is too problematic to provide any useful evidence on the effects of intervention </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study is judged to be at critical risk of bias in at least 1 domain</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No information</b> on which to base a judgement about risk of bias </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is no clear indication that the study is at serious or critical risk of bias, and there is a lack of information in 1 or more key domains of bias (a judgement is required for this) </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria for overall risk of bias judgements from ROBINS‐I</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010682-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias judgements for non‐randomised studies (ROBINS‐I)</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Domain and risk of bias judgement</b>  </p> </th> <th align="left" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010682-bbs2-0002" title="HovorkaJ , HermanE , NemcovaI . Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior2000;1:444-7. ">Hovorka 2000</a><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b><a href="./references#CD010682-bbs2-0003" title="KannerA , KozakA , FreyM . The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behavior2000;1:100-5. ">Kanner 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010682-bbs2-0004" title="KuhnK , QuednowB , ThielM , FalkaiP , MaierW , ElgerC . Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior2003;4:674-9. ">Kuhn 2003</a>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010682-bbs2-0006" title="Orjuela-RojasJM , Martinez-JuarezIE , Ruiz-ChowA , Crail-MelendezD . Treatment of depression in patients with temporal lobe epilepsy: a pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors. Epilepsy &amp; Behavior2015;51:176-81. [DOI: 10.1016/j.yebeh.2015.07.033] [PMID: 26284748]">Orjuela‐Rojas 2015</a>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010682-bbs2-0008" title="SpecchioL , IudiceA , SpecchioN , La NeveA , SpinelliA , GalliR , et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology2004;27(3):133-6. ">Specchio 2004</a>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> </b><a href="./references#CD010682-bbs2-0009" title="Thome-SouzaM , KuczynskiE , ValenteK . Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy &amp; Behavior2007;10:417-25. ">Thome‐Souza 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias due to confounding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias in selection of participants into the study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias in classification of interventions</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias due to deviations from intended interventions</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias due to missing data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias in measurement of outcomes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias in selection of the reported result</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall judgement</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Support for judgement</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adjustment for confounding; unclear if participants were recruited consecutively; and by design, blinding was not possible, which may have influenced subjectively‐assessed outcomes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some analyses to investigate prognostic variables, but not a complete analysis of confounders; unclear which variables were of interest in advance, and if other characteristics were tested and analysed; and by design, blinding was not possible, which may have influenced subjectively‐assessed outcomes. The measure of depression was not an accurate or reliable measure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adjustment for confounding; many discontinuations due to adverse events and non‐compliance, with outcome data analysed by last observation carried forward; unclear if participants were already receiving the intervention on entry into the study, and exactly how groups were assigned. Lack of blinding may have influenced some participant‐reported outcomes. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some analyses to investigate prognostic variables, but not a complete analysis of confounders; unclear which variables were of interest in advance, and if other characteristics were tested and analysed; small groups and dropouts, with outcome data analysed by last observation carried forward, Lack of blinding may have influenced some participant‐reported outcomes. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adjustment for confounding; outcome data included only for those who completed analysis (6 participants excluded); and by design, blinding was not possible, which may have influenced subjectively‐assessed outcomes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No adjustment for confounding; unclear if participants were recruited consecutively; and by design, blinding was not possible, which may have influenced subjectively‐assessed outcomes. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias judgements for non‐randomised studies (ROBINS‐I)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/full#CD010682-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010682-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">RCT: paroxetine versus doxepin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 &gt; 50% reduction in depressive symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.88, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Mean depression scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 HAMD scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [‐2.15, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Withdrawals (any reason) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.09, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.03, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.06, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Sleep disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.08, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.5 Urinary retention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 21.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">RCT: paroxetine versus doxepin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010682-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">RCT: amitriptyline versus nomifensine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 &gt; 50% reduction in depressive symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.28, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">RCT: amitriptyline versus nomifensine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010682-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">RCT: venlafaxine versus no treatment controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 &gt; 50% reduction in depressive symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.25 [1.19, 8.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Mean depression scores ‐ HAMD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.59 [‐11.52, ‐3.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">RCT: venlafaxine versus no treatment controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010682-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">RCT: sertraline versus cognitive behavioural therapy (CBT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Mean depression scores (BDI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 BDI‐II scores at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐6.28, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 BDI‐II scores at 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐4.47, 3.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Remission in depressive symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.65, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Seizure frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Generalised tonic‐clonic seizures per month at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.26, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Generalised tonic‐clonic seizures per month at 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.10, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 Focal seizures with impaired awareness per month at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐6.52, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 Focal seizures with impaired awareness per month at 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.00 [‐7.81, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Seizure recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.27, 3.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Withdrawals (any reason) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.64, 2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Quality of life (QOLIE‐89) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 QOLIE‐89 score at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [‐0.28, 12.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 QOLIE‐89 score at 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [‐3.41, 9.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Adverse events profile <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Adverse event profile at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.70 [‐6.62, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Adverse event profile at 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐6.21, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.51 [0.19, 386.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 Chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.05, 4.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.3 Cold</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.13, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.4 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.85 [0.49, 805.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.5 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.37, 6.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.6 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.78 [0.22, 65.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.7 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.69, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.8 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.73, 6.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.9 Memory difficulty</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.10, 4.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.10 Muscle strain or pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.36, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.11 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [0.62, 10.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.12 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.72 [0.29, 76.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.13 Sexual dysfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.51 [0.19, 386.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.14 Shakiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.28 [0.88, 171.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.15 Tiredness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.54 [1.40, 8.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.16 Unsteadiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.25, 9.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.17 Worsening depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.25, 5.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">RCT: sertraline versus cognitive behavioural therapy (CBT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010682-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">NRSI: citalopram (before and after)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Mean depression scores HAMD‐21 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.96, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Mean monthly seizure frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">NRSI: citalopram (before and after)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010682-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">NRSI: SSRIs (sertraline or citalopram) versus CBT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Mean depression scores (BDI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 BDI at 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐11.58, 6.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 BDI at 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.90 [‐14.60, 4.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Remission in depressive symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.77, 3.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Seizure frequency per month at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐5.63, 2.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Withdrawals (any reason) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.05, 3.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Quality of life (QOLIE‐31 overall score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐19.67, 18.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">NRSI: SSRIs (sertraline or citalopram) versus CBT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010682.pub3/references#CD010682-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010682.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010682-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010682-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010682-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010682-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD010682-note-0013">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD010682-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD010682-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD010682-note-0010">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD010682-note-0009">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010682\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010682\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010682\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010682\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010682\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010682.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010682.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010682.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010682.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010682.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729088763"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010682.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729088767"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010682.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed4554863f56f',t:'MTc0MDcyOTA4OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 